Prognosis_ID,Topography,Short_topo,Morphology,Country,Population,Region,Development,Institution,Period,InclusionCriteria,Treatment,MedianFU,RangeFU,Cohort,P53_mutation,Parameter_analysed,Association,Result,Ref_ID,Cross_Ref_ID,Title,Authors,S_Ref_Year,Journal,Volume,Start_page,End_page,PubMed,Comment,Tissue_processing,Start_material,Prescreening,Material_sequenced,exon2,exon3,exon4,exon5,exon6,exon7,exon8,exon9,exon10,exon11,Exclude_analysis
198,ADRENAL GLAND,ADRENAL GLAND,Adrenal cortical carcinoma (C74.0),France,Western Europe,Europe,More developed regions,"Cochin Hospital, Paris",,17p13 LOH cases,,63.0,1-119,36,12,survival,associated with bad,"Tumors with a TP53 mutation had a shorter disease-free survival as determined by univariate analysis (P = 0.03; Fig. 3A). Nevertheless, overall survival was not significantly different between the TP53-mutant and TP53 wild-type tumors (P = 0.25, log-rank test).",2400,2400,Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity,Libe R;Groussin L;Tissier F;Elie C;Rene-Corail F;Fratticci A;Jullian E;Beck-Peccoz P;Bertagna X;Gicquel C;Bertherat J;,2007,Clin Cancer Res,13,844,850,17289876,,frozen,DNA/RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
99,BLADDER,BLADDER,"Carcinoma, NOS",The Netherlands,Western Europe,Europe,More developed regions,University Hospital Nijmegen,<1994,,"SU, CX/RX",,,45,8,survival,associated with bad,"Eight out of 24 invasive tumours appeared to have a p53 mutation, while no p53 mutations were found in the superficial tumours….A significant correlation between mutated p53 and poor survival in the whole group studied was found (P < 0.001, log-rank test). However, within the group of muscle-invasive tumours the occurrence of p53 mutations had no additional prognostic value.",395,395,p53 mutations have no additional prognostic value over stage in bladder cancer,Vet JA;Bringuier PP;Poddighe PJ;Karthaus HF;Debruyne FM;Schalken JA;,1994,Br J Cancer,70,496,500,0008080737,IHC in ref 661,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
100,BLADDER,BLADDER,"Transitional cell carcinoma, NOS",UK,Northern Europe,Europe,More developed regions,"Freeman Hospital, Newcastle Upon Tyne",<1998,,,,0-85,54,18,survival,not related to,"There was a significant association between TP53 immunoreactivity in more than 50% of tumour cell nuclei and decreased survival among all patients (P = 0.0325; log-rank test). The patients with TP53 mutations showed a trend for a shorter survival period; however, the association was not statistically significant at the 95% confidence level (P = 0.132; log- rank test).",985,,Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis,Abdel-Fattah R;Challen C;Griffiths TR;Robinson MC;Neal DE;Lunec J;,1998,Br J Cancer,77,2230,2238,0009649138,,frozen,DNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
44,BLADDER,BLADDER,"Cancer, NOS",Japan,Eastern Asia,Asia,More developed regions,"Kitasato University School of Medecine, Sagamihara",<1995,consecutive primary cancers,,,0-72,105,38,survival,associated with bad,"Significant differences were found for groups with grades 1 and 2 to 3 (p < 0.05) cancer, stages pT1 and pT2 to 4 (p < 0.01) disease, and with and without p53 gene mutations (p < 0.01, Cox-Mantel test). Unfavorable prognostic factor may possibly be linked not only to histopathological findings but the presence of a p53 mutation in bladder tumors as well.",1240,513,[p53 tumor suppressor gene mutation and prognosis in 105 cases of bladder cancer--the relationship between mutation of the p53 gene with clinicopathological features and smoking],Harano H;Wang C;Gao J;Uchida T;,1999,Nippon Hinyokika Gakkai Zasshi,90,487,495,0010355250,,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,false,false,false
114,BLADDER,BLADDER,"Cancer, NOS",Poland,Eastern Europe,Europe,More developed regions,Medical University of Gdansk,,primary cancer,SU,,0-36,61,16,survival,associated with bad,"There was an association between the p53 mutations and shorter OS (P = 0.033; log-rank test); however in a multivariate analysis adjusted for stage, grade, lymph node status and age the p53 mutation was not an independent predictor of survival. There was no correlation of the p53 status with decreased disease-free survival (P = 0.8; log-rank test).",1948,,Clinical implications of p53 mutation analysis in bladder cancer tissue and urine sediment by functional assay in yeast,Schlichtholz B;Presler M;Matuszewski M;,2004,Carcinogenesis,25,2319,2323,15308588,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
127,BLADDER,BLADDER,"Transitional cell carcinoma, NOS",Spain,Southern Europe,Europe,More developed regions,18 general hospitals in Spain,1997-2001,T1G3 cases,SU,54.0,38-72,119,78,recurrence/survival,not related to,"FGFR3 and Tp53 mutations were not associated with clinicopathologic characteristics of patients and did not predict, alone or in combination, recurrence or survival. Taking the risk of the wt/wt group as reference, the mutation-associated risks of cancer-specific mortality were: mut/wt 1.42 (0.15-13.75), wt/mut 0.67 (0.19-2.31), mut/mut 1.62 (0.27-9.59). These molecular features support the notion that T1G3 tumors are at the crossroads of the two main molecular pathways proposed for bladder cancer development and progression.",2085,,FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis,Hernandez S;Lopez-Knowles E;Lloreta J;Kogevinas M;Jaramillo R;Amoros A;Tardon A;Garcia-Closas R;Serra C;Carrato A;Malats N;Real FX;,2005,Clin Cancer Res,11,5444,5450,16061860,"Completed with additional data from Lopez-Knowles E et al, 2006, Clin Cancer Res",fixed,DNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
137,BLADDER,BLADDER,"Transitional cell carcinoma, NOS",Czech Republic,Eastern Europe,Europe,More developed regions,Prague,2000-2002,Ta or T1 stage + one or more tumor recurrence during the FU period,"SU, CX or BCG",,0-56,25,4,recurrence,not related to,No statiscally significant correlation between TP53 mutations or LOH on 17p13 and disease progression or disease generalization was found.,2129,1910,Analysis of genetic events in 17p13 and 9p21 regions supports predominant monoclonal origin of multifocal and recurrent bladder cancer,Trkova M;Babjuk M;Duskova J;Benesova-Minarikova L;Soukup V;Mares J;Minarik M;Sedlacek Z;,2005,Cancer Lett,242,68,76,16343743,,frozen,DNA,none,direct,false,false,false,true,true,true,true,true,false,false,false
55,BLADDER,BLADDER,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"Memorial Sloan-Kettering Cancer Center, NY",1993-1997,prospective study;,"SU, CX",33.0,5-120,125,58,survival,not related to,"No obvious difference was found between the FGFR4 genotype or TP53 mutations and the disease-specific survival. The combination of both markers, however, was strongly associated with the disease-specific survival. FGFR4 Gly388 homozygous patients with TP53 mutation (median survival time = 14.2 months) had a hazard ratio of 1.85 (95% CI, 1.01-3.39) for disease-specific survival compared with the reference group, which consisted of Gly388 homozygote without TP53 mutation and Arg388 allele carriers with or without TP53 mutation (median surival time = 23.3, 23.9 and 31.5 months, respectively).",2340,1626,Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis,Yang YC;Lu ML;Rao JY;Wallerand H;Cai L;Cao W;Pantuck A;Dalbagni G;Reuter V;Figlin RA;Belldegrun A;Cordon-Cardo C;Zhang ZF;,2006,Br J Cancer,95,1455,1458,17088904,,frozen,DNA,SSCP/AmpliChip,direct,true,true,true,true,true,true,true,true,true,true,false
189,BLADDER,BLADDER,"Neoplasm, NOS",Spain,Southern Europe,Europe,More developed regions,"Fundacion Instituto Valenciano de Oncologica, Valencia",,,,36.4,"1,3-49,2",84,9,recurrence/survival,associated with bad,"Progression was found in 44,4% (4 of 9 patients) with p5"" mutation, higher than in the group with a wild-type p53 - 16,0% (12 of 75 patients) (p=0,04). Patients with mutated p53 showed a worse 3-year overall survival and progression-free survival when compared to patients without p53 mutation (p=0,03 and p=0,05 respectively); no relationship was found regarding recurrence-free survival (p=0,81).",2342,,Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder,Yurakh AO;Ramos D;Calabuig-Farinas S;Lopez-Guerrero JA;Rubio J;Solsona E;Romanenko AM;Vozianov AF;Pellin A;Llombart-Bosch A;,2006,Eur Urol,50,506,515,16624482,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
200,BLADDER,BLADDER,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"University of Southern California, Norris Comprehensive Cancer Center",1983-1988,radical cystectomy,,,1-240,150,55,recurrence,associated with bad,"Patients with TP53 gene mutations were more likely to experience recurrence (P<0,004).",2402,,p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer,George B;Datar RH;Wu L;Cai J;Patten N;Beil SJ;Groshen S;Stein J;Skinner D;Jones PA;Cote RJ;,2007,J Clin Oncol,25,5352,5358,18048815,,fixed,DNA,AmpliChip,direct,true,true,true,true,true,true,true,true,true,true,false
136,"BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS",BONES (limbs),"Osteosarcoma, NOS (C40._, C41._)","Northern America, NOS",Northern America,Americas,More developed regions,"Mount Sinai Hospital, Toronto, Canada; Vancouver Hospital seven tertiary care institutions from USA and Canada",1989-1998,"high grade, non-metastatic, biopsy-proven diagnosed","SU, CX (doxo/CISP; MTX/doxo/CISP; ifosfamide/MTX/doxo/CISP)",44.0,0-84,196,38,recurrence/survival,not related to,"We found no evidence that TP53 mutations predict for development of metastases in patients with high-grade osteosarcoma: no relationship was identified between TP53 status and systemic relapse (relative risk, 1.24; P = .41). Analyses based on missense or nonsense mutations gave similar results (P > .10).  Patient age was the only factor that varied with TP53 gene status (P = .05).",2126,1622,"TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study",Wunder JS;Gokgoz N;Parkes R;Bull SB;Eskandarian S;Davis AM;Beauchamp CP;Conrad EU;Grimer RJ;Healey JH;Malkin D;Mangham DC;Rock MJ;Bell RS;Andrulis IL;,2005,J Clin Oncol,23,1483,1490,15735124,,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,true,false,false
161,"BONES, JOINTS AND ARTICULAR CARTILAGE OF LIMBS",BONES (limbs),Ewing sarcoma,USA,Northern America,Americas,More developed regions,"Memorial Sloan-Kettering Cancer Center, NY",1991-2001,1) presence of EWS-FL11 or EWS-ERG fusion transcripts; 2° adequate follow up information,"SU, pre-op CX",29.0,6-118,60,8,survival/response,associated with bad,"Good chemotherapeutic effect was correlated with the absence of either p53 or p16/p14ARF alterations (p=0,03, Fisher's exact test). By univariate analysis, stage (p<0,001); risk ratioo RR=2,2; 95%CI, 1,4 to 3,7), p53 mutation (p<0,001; RR=3,7; 95%CI, 2,1 to 4,6) and either or both of a p53 or p16 alteration (p<0,001; RR=2,5; 95%CI, 1,6 to 3,8) were strong negative predictors of overall survival. In the multivariate analysis, the presence of p53 mutation (p>,001; RR=3,9; 95%CI, 1,9 to 8,0) remained the most significant independent prognostic factor.",2184,,Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse,Huang HY;Illei PB;Zhao Z;Mazumdar M;Huvos AG;Healey JH;Wexler LH;Gorlick R;Meyers P;Ladanyi M;,2005,J Clin Oncol,23,548,558,15659501,,frozen,DNA,IHC,direct,true,true,true,true,true,true,true,true,true,true,false
53,BRAIN,BRAIN,"Astrocytoma, NOS (C71._)",Germany,Western Europe,Europe,More developed regions,"Heinrich-Heine University, Dusseldorf",,consecutive primary cancers; grade II gliomas that progressed to high grade,SU,32.0,14-94,22,12,recurrence,associated with bad,p53 is mutated in a high fraction of low-grade astrocytomas with progression to anaplastic astrocytomas and glioblastomas and progression in such cases is frequently associated with an increase in the fraction of p53 immunopositive tumor cells.,858,,Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression,Reifenberger J;Ring GU;Gies U;Cobbers L;Oberstrass J;An HX;Niederacher D;Wechsler W;Reifenberger G;,1996,J Neuropathol Exp Neurol,55,822,831,0008965097,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
51,BRAIN,BRAIN,"Astrocytoma, NOS (C71._)",Switzerland,Western Europe,Europe,More developed regions,"University Hospital (CHUV), Lausanne",1983-1995,consecutive primary cancers; low grade astrocytomas,"SU, RX for 8 patients",72.0,12-186,36,14,survival,associated with bad,"The presence of TP53 mutations in WHO grade II astrocytic tumors was associated with malignant progression (P=0. 034, chi2 test) and shorter progression-free survival (PFS; 47.6+/-9. 6 months for TP53-mutated tumors vs 67.8+/-8.2 months for TP53-wild type tumors, P<0.05, log-rank test)...Our study also indicates that irradiation for WHO grade II astrocytic tumors might be associated with poor outcome (P<0.0001) and this was independent of TP53 status.",1310,,Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor,Ishii N;Tada M;Hamou MF;Janzer RC;Meagher-Villemure K;Wiestler OD;Tribolet N;Van Meir EG;,1999,Oncogene,18,5870,5878,0010557074,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
56,BRAIN,BRAIN,"Glioma, malignant (C71._)",USA,Northern America,Americas,More developed regions,Cooperative Human Tissue Network (CCG-945),1985-1990,children with non-brain-stem malignant gliomas,"SU, RX, CX",,0-144,121,40,survival,not related to,We found a significant association between overexpression of p53 and outcome. A nonsignificant association was observed between mutations in TP53 and outcome.,1654,1577,Expression of p53 and prognosis in children with malignant gliomas,Pollack IF;Finkelstein SD;Woods J;Burnham J;Holmes EJ;Hamilton RL;Yates AJ;Boyett JM;Finlay JL;Sposto R;,2002,N Engl J Med,346,420,427,11832530,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
59,BRAIN,BRAIN,"Astrocytoma, NOS (C71._)",USA,Northern America,Americas,More developed regions,,,Grade 3-4 astrocytomas,"SU, RX, CX",,,167,33,survival,associated with good,"Mutation of p53 was statistically significantly more common in anaplastic astrocytoma than in glioblastoma multiforme (P<.001). Univariate survival analyses of patients with anaplastic astrocytoma identified PTEN (P =.002) and p53 (P =.012) mutations as statistically significantly associated with reduced and prolonged survival, respectively. In multivariate analysis, p53 alterations were consistently shown to be moderately associated with better survival.",1656,,"PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme",Smith JS;Tachibana I;Passe SM;Huntley BK;Borell TJ;Iturria N;O'Fallon JR;Schaefer PL;Scheithauer BW;James CD;Buckner JC;Jenkins RB;,2001,J Natl Cancer Inst,93,1246,1256,11504770,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
71,BRAIN,BRAIN,"Glioblastoma, NOS (C71._)",Germany,Western Europe,Europe,More developed regions,"University of Bonn, University of Madgeburg, University of Wurzburg, University of Kiel",1981-1998,Grade 4 glioblastomas,"SU, RX, CX",,,89,20,survival,not related to,"TP53 mutations were found in 12 out of 54 (22%) GBMs of short-term survivors and 8 out of 35 (23%) tumors of long-term survivors; the respective numbers for nuclear p53 protein accumulation were 12/53 (23%) and 10/37 (27%). Waf1/p21 expression was found in 13/53 (25%) tumors of short-term survivors and 9/35 (26%) GBMs of long-term survivors. The respective numbers for Bcl-2 expression were 25/42 (60%) and 22/36 (61%) and for CD95 (Apo1/Fas) expression 20/49 (41%) and 14/36 (39%) GBMs. The percentage of alterations in genes/proteins involved in the apoptotic pathway investigated here was virtually identical in the two groups of clinically different GBM patients. Thus, our data imply that none of these alterations investigated per se has a strong impact on the overall survival of GBM patients.",1682,,"TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme",Kraus JA;Wenghoefer M;Glesmann N;Mohr S;Beck M;Schmidt MC;Schroder R;Berweiler U;Roggendorf W;Diete S;Dietzmann K;Heuser K;Muller B;Fimmers R;von Deimling A;Schlegel U;,2001,J Neurooncol,52,263,272,11519857,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
73,BRAIN,BRAIN,"Astrocytoma, NOS (C71._)",Germany,Western Europe,Europe,More developed regions,"Ludwig-Maximilians University, Munich",1991-1998,supratentorial WHO grade II astrocytomas or oligoastrocytomas,SU,49.0,0-96,149,73,survival,not related to,"Univariately, gemistocytic subtype and presence of TP53 mutation (but not P53 accumulation) were unfavorable predictors for progression-free survival (P < 0.05); multivariately, only the gemistocytic subtype remained unfavorable influence (P = 0.04). No overall prognostic impact of the TP53 status on survival and time to malignancy was observed (P < 0.05). Five nongemistocytic tumors with a codon 175 TP53 mutation exhibited a significantly worse prognosis as compared with those with any other mutational sites (5-year progression-free survival: 0%; 5-year malignant transformation: 100%; P < 0.001).",1704,,Prognostic Impact of TP53 Mutations and P53 Protein Overexpression in Supratentorial WHO Grade II Astrocytomas and Oligoastrocytomas,Peraud A;Kreth FW;Wiestler OD;Kleihues P;Reulen HJ;,2002,Clin Cancer Res,8,1117,1124,12006527,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
74,BRAIN,BRAIN,"Glioblastoma, NOS (C71._)",Germany,Western Europe,Europe,More developed regions,University of Bonn Medical Center,1992-1996,consecutively operated cancers,SU,10.0,0-60,87,16,survival,associated with good,"Among the molecular parameters, TP53 mutations and LOH10q emerged as favorable and poor prognostic factors, respectively. TP53 mutations were a favorable prognostic factor independent of whether glioblastomas were primary or secondary.",1705,,Impact of genotype and morphology on the prognosis of glioblastoma,Schmidt MC;Antweiler S;Urban N;Mueller W;Kuklik A;Meyer-Puttlitz B;Wiestler OD;Louis DN;Fimmers R;von Deimling A;,2002,J Neuropathol Exp Neurol,61,321,328,11939587,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
76,BRAIN,BRAIN,"Glioblastoma, NOS (C71._)",Japan,Eastern Asia,Asia,More developed regions,Kumamoto University Hospital,1995-2000,consecutive primary cancers,"SU, RX, CX",,,55,17,survival,not related to,the mutation did not affect progression free survival or overall survival.,1726,,Influence of p53 mutations on prognosis of patients with glioblastoma,Shiraishi S;Tada K;Nakamura H;Makino K;Kochi M;Saya H;Kuratsu J;Ushio Y;,2002,Cancer,95,249,257,12124823,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
85,BRAIN,BRAIN,"Astrocytoma, NOS (C71._)",Japan,Eastern Asia,Asia,More developed regions,"Nihon University School of Medecine, Tokyo",1981-1998,WHO grade II,"SU, RX, IFN",90.0,36-225,46,25,survival,not related to,"The TP53/MDM2/p14(ARF) pathway was altered in 32 of 46 cases (70%) by either TP53 mutation (25 cases) or p14(ARF) methylation (9 cases). The RB1/CDK4/p16(INK4a)/p15(INK4b) pathway was disrupted in 6 of 46 cases (13%) by either RB1 methylation (1 case), p16(INK4a) methylation (3 cases), or p15(INK4b) methylation or homozygous deletion (3 cases). Generally speaking, individual tumors thus tended to display alteration of only one component from both pathways. Any independently analyzed genetic alteration failed to provide statistically prognostic information. The alternate or simultaneous presence of TP53 mutation and p14(ARF) methylation emerged as a univariate predictor of a shorter progression-free survival (P = 0.0456) but was not statistically significant when age and extent of surgery were included in the analysis.",1812,,Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course,Watanabe T;Katayama Y;Yoshino A;Komine C;Yokoyama T;,2003,Clin Cancer Res,9,4884,4890,14581362,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
107,BRAIN,BRAIN,"Glioblastoma, NOS (C71._)",USA,Northern America,Americas,More developed regions,Massachusetts General Hospital Brain Tumor Center,1990-2001,consecutive series of glioblastomas,SU; RX; CX(in some patients),,0-70,134,24,survival,associated with bad,"TP53 mutation was significantly associated with patient age, subjects with TP53 mutation being younger at diagnosis compared to those without TP53 mutation (P <0.05). The prognostic effects of TP53 mutation was dependent on the age of the patient. In patients above 70 years, TP53 alterations were associated with reduced survival [hazard ratio = 7.54; 95% confidence interval (CI), 2.38–23.87], whereas the opposite was true in patients below 70 years (hazard ratio = 0.84; 95% CI, 0.49–1.42).",1931,,Age-dependent prognostic effects of genetic alterations in glioblastoma,Batchelor TT;Betensky RA;Esposito JM;Pham LD;Dorfman MV;Piscatelli N;Jhung S;Rhee D;Louis DN;,2004,Clin Cancer Res,10,228,233,14734474,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
133,BRAIN,BRAIN,"Astrocytoma, anaplastic (C71._)",Italy,Southern Europe,Europe,More developed regions,"Karolinska Hospital, Stockholm and Sahlgrenska University Hospital, Gothenburg",1989-1994,,,,124-168,37,26,survival,not related to,We did not find any clear associations between TP53 mutation and survival in any of the comparisons.,2097,1342,Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas,Backlund LM;Nilsson BR;Liu L;Ichimura K;Collins VP;,2005,Br J Cancer,93,124,130,15970925,,frozen,DNA,DGGE,direct,true,true,true,true,true,true,true,true,true,true,false
148,BRAIN,BRAIN,"Oligodendroglioma, NOS (C71._)",USA,Northern America,Americas,More developed regions,"Duke University Medical Center, Durham, North Carolina",,,,,0-150,46,6,recurrence/survival,associated with bad,TP53 mutation was found to be significantly predictive of a shorter survival (P = 0.027) among all patients and exhibited a strong trend toward a shorter PFS (P = 0.060).,2139,337,Survival analysis of presumptive prognostic markers among oligodendrogliomas,McLendon RE;Herndon JE;West B;Reardon D;Wiltshire R;Rasheed BK;Quinn J;Friedman HS;Friedman AH;Bigner DD;,2005,Cancer,104,1693,1699,16116609,See also ref 1272,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
155,BRAIN,BRAIN,"Glioma, malignant (C71._)",UK,Northern Europe,Europe,More developed regions,"The Walton Centre for Neurology and Neurosurgery, Liverpool",2000-2003,grade II oliogastrocytomas and oligodendrogliomas,"SU, CX, RX",,,51,19,survival,associated with bad,"Loss of 1p36 and 19q13 (p=0,0046) and p53 mutation (p=0,0075) were significantly associated with shorter survival from presentation in Kaplan-Meier analysis.",2165,,Molecular pathology and clinical characteristics of oligodendroglial neoplasms,Walker C;du Plessis DG;Joyce KA;Fildes D;Gee A;Haylock B;Husband D;Smith T;Broome J;Warnke PC;,2005,Ann Neurol,57,855,865,15929038,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
177,BRAIN,BRAIN,"Glioblastoma, NOS (C71._)",NA,NA,NA,NA,"Neurosurgical Units at Dunedin, Christchurch, Auckland (New Zealand), Hull and Sheffield (UK)",1997-2005,,"SU, RX (60 Gy fractionated)",8.0,,97,26,survival,associated with bad,"TP53 mutations alone affected the overall survival of glioblastoma multiforme patients. The median survival of glioblastoma multiforme patients carrying TP53 mutation versus those with WT TP53 was 12,2 and 7,6 months [ratio: 1,599, 95% CI: 0,9713-2,226; P=0,0032]. TP53 is no longer significant for outcome after adjusting for age, gender and TNM (P=0,550).",2250,,Association of mutant TP53 with alternative lengthening of telomeres and favorable prognosis in glioma,Chen YJ;Hakin-Smith V;Teo M;Xinarianos GE;Jellinek DA;Carroll T;McDowell D;MacFarlane MR;Boet R;Baguley BC;Braithwaite AW;Reddel RR;Royds JA;,2006,Cancer Res,66,6473,6476,16818615,,,DNA,SSCP/DHPLC,direct,true,true,true,true,true,true,true,true,true,true,false
4,BREAST,BREAST,"Cancer, NOS",Iceland,Northern Europe,Europe,More developed regions,"University Hospital of Iceland, Reykjavik",<1993,consecutive primary cancers,,32.0,0-60,109,18,survival,associated with bad,"There was a significant association between p53 mutation and low content of estrogen receptor protein in the tumors (P = 0.01). An association with poor prognosis was strongly indicated by mortality rates that were 37.5% among the patients with p53 mutation and 9.4% for the control group (mean follow up, 32 months). P53 mutation was found to be the strongest negative factor against survival in a covariate survival analysis (P = 0.001)",193,193,Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor,Thorlacius S;Borresen AL;Eyfjord JE;,1993,Cancer Res,53,1637,1641,0008453635,see also refID-2369,frozen,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
3,BREAST,BREAST,"Cancer, NOS",Norway,Northern Europe,Europe,More developed regions,"Norwegian Radium Hospital, Oslo",1984-1989,consecutive primary cancers,,38.3,0.1-94.1,163,35,survival,associated with bad,"TP53 alteration in primary tumour was significantly associated with the following parameters: positive node status, T status > 1, negative oestrogen receptor status, negative progesterone receptor status, presence of ERBB2 gene amplification, and invasive ductal histology. Furthermore, there were statistically significant associations, independent of other prognostic factors, between TP53 alterations in primary tumour and disease-free and overall survival.",234,66,Prognostic significance of TP53 alterations in breast carcinoma,Andersen TI;Holm R;Nesland JM;Heimdal KR;Ottestad L;Borresen AL;,1993,Br J Cancer,68,540,548,0008102535,"See also ref 1764, add info from ref 2369",frozen,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
12,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"Vanderbilt University Hospital, Nashville",1982-1991,consecutive primary cancers,"SU, CX",48.0,12-124,192,43,survival,not related to,"The overall survival rates showed no significant difference between patients with mutant and wild-type p53 tumors. The same was true when the comparison was limited to node-negative patients or patients with ER-positive or ER-negative tumors. Finally, there was no significant difference in survival between patients with tumors harboring mutations in exons 5 and 6 versus exons 7-9.",327,,p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment,Caleffi M;Teague MW;Jensen RA;Vnencak-Jones CL;Dupont WD;Parl FF;,1994,Cancer,73,2147,2156,0008156519,,,DNA,DGGE,direct,false,false,false,true,true,true,true,true,false,false,false
45,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,National Cancer Institute's Collaboraitve Black/White Cancer Survival Study,1985-1986,Black/White Cancer Survival Study,"SU, RX, CX",,0-80,92,18,survival,associated with bad,"Significantly poorer survival associated with p53 gene alterations was observed for blacks (P = 0.012), but not for whites. Black patients with p53 alterations had a significant 4-5-fold excess risk of death from breast cancer than those without p53 alterations. Adjustment for stage, age, tumor histopathology, receptor status, and adjuvant treatment did not change the excess risk.",507,,Racial disparity in the association of p53 gene alterations with breast cancer survival,Shiao YH;Chen VW;Scheer WD;Wu XC;Correa P;,1995,Cancer Res,55,1485,1490,0007882357,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
7,BREAST,BREAST,"Cancer, NOS",The Netherlands,Western Europe,Europe,More developed regions,Rotterdam Cancer Institute,1978-1991,consecutive primary cancers,"SU, CX (CMF; CAF); TAM",115.0,47-183,177,53,survival/response,associated with bad,"In a Cox univariate analysis, TP53 gene mutation was significantly associated with poor relapse-free survival (RFS: P = 0.02) but not with overall survival (OS: P = 0.07). In a Cox multivariate analysis, including classical prognostic factors, TP53 gene mutation independently predicted poor RFS and OS (RHR = 1.8 and 1.6 respectively). Unexpectedly, the median relapse-free survival of patients with a polymorphism at codon 213 or with a silent mutation was shorter (median 11 months) than the median relapse-free survival of patients with or without a TP53 gene mutation (median 34 or 48 months respectively). In an exploratory subset analysis, mutations in codons that directly contact DNA were related with the poorest relapse-free (P < 0.05) and overall survival (P < 0.02).",1003,1003,Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer,Berns EM;van Staveren IL;Look MP;Smid M;Klijn JG;Foekens JA;,1998,Br J Cancer,77,1130,1136,0009569050,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
46,BREAST,BREAST,"Cancer, NOS",France,Western Europe,Europe,More developed regions,"Curie Institute, Paris",1991-1993,consecutive primary cancers,"SU, CX (5FU+doxo+CP); RX",,0-70,64,20,survival,not related to,"Most patients with wild-type p53 tumors were found to be resistant to neoadjuvant chemotherapy. No correlation between distant disease-free survival and p53 status or intrinsic MDR1 gene expression was found. Poor overall survival was observed in patients with tumors with high SPF (P < 0.0004) or lacking MDR1 gene expression (P = 0.03) before treatment, but not with p53 alterations.",1035,,"Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy",Chevillard S;Lebeau J;Pouillart P;de Toma C;Beldjord C;Asselain B;Klijanienko J;Fourquet A;Magdelenat H;Vielh P;,1997,Clin Cancer Res,3,2471,2478,0009815649,,fixed,RNA,DGGE,direct,false,false,false,true,true,true,true,true,false,false,false
11,BREAST,BREAST,"Cancer, NOS",France,Western Europe,Europe,More developed regions,"Centre Leon Berard, Lyon",,consecutive primary cancers,"SU, RX, CX (CAF)",105.0,0-250,113,18,survival,associated with bad,P53 gene mutation was an independent prognostic marker of early relapse and death,1052,,Prognostic value of P53 gene mutations in a large series of node- negative breast cancer patients,Falette N;Paperin MP;Treilleux I;Gratadour AC;Peloux N;Mignotte H;Tooke N;Lofman E;Inganas M;Bremond A;Ozturk M;Puisieux A;,1998,Cancer Res,58,1451,1455,0009537247,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
10,BREAST,BREAST,"Cancer, NOS",Austria,Western Europe,Europe,More developed regions,Vienna Medical School,1984-1990,consecutive primary cancers; ER pos.,"SU, CX (CMF)",107.0,0-168,205,42,survival,associated with bad,"p53 mutation served as a statistically significant parameter in predicting disease-free survival in univariate (P = 0.02) and multivariate (P = 0.009) analysis. For overall survival, no significant differences were observed. Patients with tumours that had p53 mutations within the L2/L3 domains of the gene showed no significant difference to those with mutations outside the L2/L3 domains for disease-free survival. For overall survival, mutations in the L2/L3 domains showed a marginally significant difference (P = 0.05) in multivariate analysis, but not in univariate analysis (P = 0.13).",1173,,"Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group",Kucera E;Speiser P;Gnant M;Szabo L;Samonigg H;Hausmaninger H;Mittlbock M;Fridrik M;Seifert M;Kubista E;Reiner A;Zeillinger R;Jakesz R;,1999,Eur J Cancer,35,398,405,0010448289,,fixed,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
41,BREAST,BREAST,"Cancer, NOS",Sweden,Northern Europe,Europe,More developed regions,South-east Health Care Centers,1980-1993,early onset breast cancers (<=37yo),,67.0,,123,21,survival,associated with bad,"Log rank analysis revealed no significant association between survival and TP53 mutations (in general), p53 protein accumulation or LOH. However, missense mutations localised to the zinc binding domain were significantly (P = 0.0007) associated with poorer prognosis.",1269,1269,"p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation",Gentile M;Jungestrom MB;Olsen KE;Soderkvist P;Wingren S;,1999,Eur J Cancer,35,1202,1207,10615230,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
101,BREAST,BREAST,"Cancer, NOS",Switzerland,Western Europe,Europe,More developed regions,Geneva University Hospital,1987-1989,consecutive primary cancers,"SU, RX",88.0,5-112,153,58,survival,associated with bad,Multivariate analysis of 153 patients for whom full data were available showed that p53 status contributed prognostic information when tumour size and lymph node status were taken into account but not when histological grade was included. p53 status thus contributes only limited new prognostic information in breast cancer when established prognostic factors are taken into account.,1293,,Prognostic significance of p53 mutation in breast cancer: frequent detection of non-missense mutations by yeast functional assay,Chappuis PO;Estreicher A;Dieterich B;Bonnefoi H;Otter M;Sappino AP;Iggo R;,1999,Int J Cancer,84,587,593,0010567903,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
2,BREAST,BREAST,"Cancer, NOS",Japan,Eastern Asia,Asia,More developed regions,"Hokkaido University Hospital, Sapporo",1991-1996,consecutive primary cancers,CX (5FU;TAM;LH-RH),43.0,6-81,76,30,survival,associated with bad,"p53 mutations were associated with a short overall survival (log rank test, p = 0.0319), whereas it was not related to disease-free (recurrence-free) survival. Contact mutants were associated with slightly shorter survival compared with structural mutants. The patients with tumors harboring both p53 mutation and loss of estrogen receptor had the poorest outcome (p = 0.0019 and 0.0075 for overall and disease-free survivals, respectively).",1346,1099,Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers,Takahashi M;Tonoki H;Tada M;Kashiwazaki H;Furuuchi K;Hamada J;Fujioka Y;Sato Y;Takahashi H;Todo S;Sakuragi N;Moriuchi T;,2000,Int J Cancer,89,92,99,0010719737,,frozen,RNA,FASAY,cloned,false,false,true,true,true,true,true,true,true,false,false
216,BREAST,BREAST,"Cancer, NOS",Austria,Western Europe,Europe,More developed regions,University of Vienna Medical school,1993-1996,T3-T4 tumors,"CX (5-FU, epirubicin, cyclophosphamide)",,,35,8,response,associated with bad,Treatment failure was related to the presence of TP53 gene mutation (p = 0.0029).,1348,,TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients,Kandioler-Eckersberger D;Ludwig C;Rudas M;Kappel S;Janschek E;Wenzel C;Schlagbauer-Wadl H;Mittlbock M;Gnant M;Steger G;Jakesz R;,2000,Clin Cancer Res,6,50,56,0010656431,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
217,BREAST,BREAST,"Cancer, NOS",Austria,Western Europe,Europe,More developed regions,University of Vienna Medical school,1993-1996,T3-T4 tumors,CX (paclitaxel),,,32,6,response,associated with good,Treatment response was related to the presence of TP53 gene mutation (p = 0.07). p53 status defined by both TP53 gene mutation and positive p53 IHC was significantly correlated with response (p= 0.01).,1348,,TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients,Kandioler-Eckersberger D;Ludwig C;Rudas M;Kappel S;Janschek E;Wenzel C;Schlagbauer-Wadl H;Mittlbock M;Gnant M;Steger G;Jakesz R;,2000,Clin Cancer Res,6,50,56,0010656431,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
9,BREAST,BREAST,"Cancer, NOS",Denmark,Northern Europe,Europe,More developed regions,Aarhus University Hospital,1992-1994,consecutive primary cancers; retrospective study,"SU, CX",,0-60,315,74,survival,associated with bad,"Although TP53 mutation in general was associated with aggressive tumor/patient characteristics, missense mutations outside any conserved or structural domain did not affect the clinical outcome (risk of disseminated disease and death). In contrast, patients with missense mutations affecting amino acids directly involved in DNA or zinc binding displayed a very aggressive clinical phenotype. Null mutations (including missense mutations disrupting the tetramerization domain) and the remaining missense mutations displayed an intermediate aggressive clinical phenotype.",1392,,Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients,Alsner J;Yilmaz M;Guldberg P;Hansen LL;Overgaard J;,2000,Clin Cancer Res,6,3923,3931,11051239,,,DNA,DGGE,direct,true,true,true,true,true,true,true,true,true,true,false
1,BREAST,BREAST,"Cancer, NOS",Australia,Australia/New Zealand,Western Pacific,More developed regions,"Charles Gairdner (Perth), Royal Perth Hospital, Flinders Medical Center (South Australia)",1987-1997,consecutive primary cancers,"SU, CX/RX",65.0,1-120,1037,178,survival,associated with bad,"Mutations within exon 4 were associated with particularly poor prognosis, possibly relating to the importance of this region in apoptosis. Mutations that caused denaturation of the protein structure were also associated with poor survival, again perhaps because of effects on apoptosis. In contrast, patients with mutations in the DNA contact region showed similar survival to that of patients with normal p53, suggesting a less important role for p53-mediated transactivation in determining tumor aggressiveness. Other mutation groups associated with poor prognosis were single-base substitutions and transversion mutations. Mutations in exon 6, exon 7, or the ""hotspot"" codons (175, 245, 248, 273) were associated with only a small reduction in patient survival compared with normal p53.",1425,969,Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer,Powell B;Soong R;Iacopetta B;Seshadri R;Smith DR;,2000,Clin Cancer Res,6,443,451,10690522,,,DNA,SSCP,direct,false,false,true,true,true,true,true,false,false,false,false
5,BREAST,BREAST,"Carcinoma, NOS",Norway,Northern Europe,Europe,More developed regions,"Norwegian Radium Hospital, Oslo",,localy advanced cancer (T3/4 and/or N2); prospective study,CX (doxo),,,90,26,response,associated with bad,"Mutations in the TP53 gene, in particular those affecting or disrupting the loop domains L2 or L3 of the p53 protein, were associated with lack of response to chemotherapy (P = 0.063 for all mutations and P = 0.008 for mutations affecting L2/L3, respectively)….",1544,583,Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer,Geisler S;Lonning PE;Aas T;Johnsen H;Fluge O;Haugen DF;Lillehaug JR;Akslen LA;Borresen-Dale AL;,2001,Cancer Res,61,2505,2512,11289122,See also ref 1764,fixed/frozen,DNA,TTGE,direct,true,true,true,true,true,true,true,true,true,true,false
6,BREAST,BREAST,"Cancer, NOS",Sweden,Northern Europe,Europe,More developed regions,University of Uppsala,1987-1989,consecutive primary cancers,"SU, RX, CX (5FU, MTX, CP)",,0-90,315,69,survival,associated with bad,"The p53 status was related to prognosis and effect of adjuvant therapy. p53 mutations in the evolutionary conserved regions II and V were associated with significantly worse prognosis. Update 2005 (Miller LD et al, 2005, PNAS): The classifier (based on proteins' function) separated patients into low and high risk groups with a much higher statistical significance than the sequence-based p53 status alone (p=0,0006 vs; p=0,01). Our analysis of genes involved in the p53 pathway suggests that the p53 expression signature defines some operational configuration of this pathway in breast tumors (more than p53 mutation status alone) that impacts patient survival and therapeutic response.",1641,992,"Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy",Bergh J;Norberg T;Sjogren S;Lindgren A;Holmberg L;,1995,Nat Med,1,1029,1034,7489358,See refs 1006 and 2369,frozen,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
8,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"Mayo Clinic, Rochester",,consecutive primary cancers; prospective study,"SU, CX (CMF, CAF)",,0-60,90,32,survival/response,associated with bad,"The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy.",1642,64,A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome,Blaszyk H;Hartmann A;Cunningham JM;Schaid D;Wold LE;Kovach JS;Sommer SS;,2000,Int J Cancer,89,32,38,10719728,"See also ref 73, 406, 467 and 613",frozen,DNA,none,direct,false,false,true,true,true,true,true,true,true,false,false
58,BREAST,BREAST,"Cancer, NOS",France,Western Europe,Europe,More developed regions,,,"locally advanced carcinomas (inflammatory carcinomas, node positve, T3-4)","SU, CX (5FU+doxo+CP)",32.0,6-68,79,19,survival,associated with bad,p53 mutations were associated with reduced disease-free survival (p = 0.0473).,1655,,"MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients",Lizard-Nacol S;Genne P;Coudert B;Riedinger JM;Arnal M;Sancy C;Brunet-Lecomte P;Fargeot P;,1999,Anticancer Res,19,3575,3581,10629655,,,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
65,BREAST,BREAST,"Cancer, NOS",China,Eastern Asia,Asia,Less developed regions,Cancer Hospital of the Shanghai Medical University,1997-1999,consecutive primary cancers,SU,,,126,46,survival,associated with bad,"p53 mutations in plasma DNA were strongly correlated with clinical stage, tumor size, lymph node (LN) metastasis, and estrogen receptor status (P < 0.05). After a median follow-up of 29 months, univariate and multivariate analysis revealed that both primary tumor and plasma DNA p53 mutations were significant prognostic factors for both relapse-free and overall survival. Furthermore, we demonstrated that patients with both primary tumor and plasma p53 mutations have the worst survival. This outcome occurs in both LN-positive and LN-negative groups.",1661,,p53 mutation in plasma DNA and its prognostic value in breast cancer patients,Shao ZM;Wu J;Shen ZZ;Nguyen M;,2001,Clin Cancer Res,7,2222,2227,11489795,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
78,BREAST,BREAST,"Cancer, NOS",Denmark,Northern Europe,Europe,More developed regions,Copenhagen City Heart Study,1976-1993,prospective study;,,67.0,,162,36,survival,not related to,There was no clear difference in overall survival between breast cancer cases with 'wild-type' and mutant p53,1731,,"Organochlorines, p53 mutations in relation to breast cancer risk and survival. A Danish cohort-nested case-controls study",Hoyer AP;Gerdes AM;Jorgensen T;Rank F;Hartvig HB;,2002,Breast Cancer Res Treat,71,59,65,11859874,,fixed,DNA,SSCP,direct,false,false,true,true,true,true,true,true,true,true,false
93,BREAST,BREAST,"Cancer, NOS",Brazil,South America,Americas,Less developed regions,"A.C. Camargo Hospital, Sao Paulo",,,,35.6,,242,33,survival,associated with bad,"No association was found between p53 gene mutation and tumor or clinical parameters independently of the ethnic group. With a median follow-up of 35.6 months for whites and 43.4 months for the blacks, no differences in overall survival were found. If white patients were stratified according to the type and location of TP53 mutations, patients with mutations affecting amino acids directly involved in DNA or Zn binding displayed a poor prognosis.",1811,,TP53 mutations in primary breast carcinomas from white and African-Brazilian patients,Nagai MA;Schaer BH;Zago MA;Araujo SW;Nishimoto IN;Salaorni S;Guerreiro Costa LN;Silva AM;Caldas Oliveira AG;Mourao NM;Brentani MM;,2003,Int J Oncol,23,189,196,12792793,,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,false,false,false
96,BREAST,BREAST,"Carcinoma, NOS",Norway,Northern Europe,Europe,More developed regions,"Haukeland University Hospital, Bergen",1993-2001,locally advanced cancer,"SU, CX (5FU; MTC)",42.0,10-103,35,18,response,associated with bad,"Mutations in the TP53 gene, in particular those affecting loop domains L2 or L3 of the p53 protein, were associated with lack of response to chemotherapy (i.e., increase in the diameter product of tumor lesion by >/=25%; P = 0.177 for all mutations and P = 0.006 for those affecting L2/L3 domains, respectively). No statistically significant correlation between TP53 LOH and response to therapy was seen.",1825,1764,TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer,Geisler S;Borresen-Dale AL;Johnsen H;Aas T;Geisler J;Akslen LA;Anker G;Lonning PE;,2003,Clin Cancer Res,9,5582,5588,14654539,,frozen,DNA,TTGE,direct,true,true,true,true,true,true,true,true,true,true,false
194,BREAST,BREAST,"Cancer, NOS",Norway,Northern Europe,Europe,More developed regions,Akershus University Hospital & Ulleval University Hospital,,,,,-168,166,28,survival,associated with bad,"A statistically significant correlation between TP53 gene mutations and positive immunohistochemistry of p53 protein was observed (p = 0.0038). Mutations of the TP53 gene, as well as positive immunoreactivity to p53, were associated with poor prognosis (mutations p = 0.053, HR = 1.8, 95% CI 0.99-3.4; positive immunoreactivity p = 0.029, HR 1.33, 95% CI 1.0-1.7; mutation and/or positive immunoreactivity p = 0.015, HR 2.1, 95% CI 1.2-3.7) when cyclin A was not included in the survival analysis. However, when cyclin A overexpression was included, alteration of the p53 protein (mutations and/or positive immunoreactivity) lost its statistical power (p = 0.088). In a stratified survival analysis the OR fell from 3.0 (95% CI 1.2-8.3, p = 0.03) in the low-expression cyclin A stratum to 1.3 (95% CI 0.42-4.1, p = 0.77) in the overexpression cyclin A stratum",1863,1764,Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time,Bukholm IR;Husdal A;Nesland JM;Langerod A;Bukholm G;,2003,Breast Cancer Res Treat,80,199,206,12908823,see also ref 1764,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
109,BREAST,BREAST,"Carcinoma, NOS",Canada,Northern America,Americas,More developed regions,Hospital in Toronto area,1987-1993,prospective study;,,85.0,55-144,547,133,survival,associated with bad,"p53 mutations were more frequent in carcinomas with neu/erbB-2 amplification: 38.9% compared with only 20.9% in those without neu/erbB-2 amplification. We found elevated risks of disease recurrence and overall mortality in patients with both p53 mutation and neu/erbB-2 amplification in their tumor compared with patients with neither or only one of the alterations. This increase persisted with adjustment for other prognostic factors (relative risk, 2.32; P =.002 for recurrence; relative risk, 2.22; P =.004 for death).",1938,840,The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer,Bull SB;Ozcelik H;Pinnaduwage D;Blackstein ME;Sutherland DA;Pritchard KI;Tzontcheva AT;Sidlofsky S;Hanna WM;Qizilbash AH;Tweeddale ME;Fine S;McCready DR;Andrulis IL;,2004,J Clin Oncol,22,86,96,14701769,,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,true,false,false
118,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,Jackson Memorial Hospital,1984-1986,primary cancer,"SU, CX (27% of patients)",,0-120,271,177,survival,associated with bad,"After adjustment for tumor stage, treatment regimen, and the number of mutations, patients with p53 mutations had significantly greater breast-cancer-specific mortality than did patients without p53 mutations (hazard ratio = 2.86; 95% confidence interval: 1.15-7.11). Further analysis of mutation characteristics showed that patients with the following mutations had significantly poorer breast cancer disease-free survival: silent/missense mixed mutations (7.95; 1.28-49.62), nonsense mutations (9.43; 1.29-69.12), transitions (3.79; 1.46-9.88), mutations in which guanine changed (3.32; 1.01-10.35), and mutations on exon 7 (6.46; 1.78-23.45).",2001,1858,Spectrum of p53 tumor suppressor gene mutations and breast cancer survival,Lai H;Ma F;Trapido E;Meng L;Lai S;,2004,Breast Cancer Res Treat,83,57,66,14997055,,fixed,DNA,none,direct/cloned,false,false,false,true,true,true,true,false,false,false,true
173,BREAST,BREAST,"Cancer, NOS",Sweden,Northern Europe,Europe,More developed regions,University of Gothenburg,1984-1989,"Node-positive primary breast cancers, no preoperative therapy, no other invasive malignancy","CX (CMF for 125 patients, TAM for 183 patients or CMF/TAM for 68 patients)",84.0,1-144,370,105,survival,associated with bad,"Univariate analyses showed TP53 to be a significant prognostic factor with regard to relapse-free, breast cancer-corrected and overall survival in all patients and in patients who received adjuvant CMF. This result was not confirmed in multivariate analysis including the following parameters: age at diagnosis, tumor size, >= 4 positive lymph nodes, ER status, PR status, S-phase fraction and level of differentiation;",2238,,Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF,Andersson J;Larsson L;Klaar S;Holmberg L;Nilsson J;Inganas M;Carlsson G;Ohd J;Rudenstam CM;Gustavsson B;Bergh J;,2005,Ann Oncol,16,743,748,15802278,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
175,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"National Cancer Institute, Bethesda",1993-2003,"Diagnosed with breast cancer within the last 6 months before recruitment, no previous history of breast cancer, MDM2 SNP309 genotype T/T",,,-130,153,31,survival,associated with bad,"Among homozygous carriers of the common MDM2 SNP309 allele (T/T), a mutant p53 status  in breast tumors was associated with a statistically significant poor survival (risk ratio [RR] of death = 2,33, 95% CI = 1,08 to 5,03)(P<0,001).",2245,,Association of breast cancer outcome with status of p53 and MDM2 SNP309,Boersma BJ;Howe TM;Goodman JE;Yfantis HG;Lee DH;Chanock SJ;Ambs S;,2006,J Natl Cancer Inst,98,911,919,16818855,,fixed,DNA,SSCP/AmpliChip,direct,true,true,true,true,true,true,true,true,true,true,false
176,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"National Cancer Institute, Bethesda",1993-2003,"Diagnosed with breast cancer within the last 6 months before recruitment, no previous history of breast cancer, MDM2 SNP309 genotype G/T or G/G",,,,92,17,survival,not related to,"Tumor p53 status was not associated with breast cancer survival among carriers of the variant MDM2 SNP309 allele (G/T or G/G): survival of case patients with tumors carrying a p53 mutation was not statistically different from that of case patients with tumors carrying a p53 mutation (P=0,65).",2245,,Association of breast cancer outcome with status of p53 and MDM2 SNP309,Boersma BJ;Howe TM;Goodman JE;Yfantis HG;Lee DH;Chanock SJ;Ambs S;,2006,J Natl Cancer Inst,98,911,919,16818855,,fixed,DNA,SSCP/AmpliChip,direct,true,true,true,true,true,true,true,true,true,true,false
178,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,University of Texas M. D. Anderson Cancer Center,2002-2005,"Newly diagnosed, non-inflammatory cancer, stage IIIA-C, palpable breast mass","SU, pre-op intratumoral injection of Ad5CMV-p53/CX",37.0,13-41,11,8,response,not related to,"All the patients showed a partial clinical response. The extent of residual disease was similar according to the p53 status of the primary tumor (median residual disease, 0,7 vs. 1,00 in p53 negative vs. P53-positive disease, respectively).",2253,,"A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach",Cristofanilli M;Krishnamurthy S;Guerra L;Broglio K;Arun B;Booser DJ;Menander K;Van Wart HJ;Valero V;Hortobagyi GN;,2006,Cancer,107,935,944,16874816,,,DNA,none/AmpliChip,direct,true,true,true,true,true,true,true,true,true,true,false
180,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,CALGB 9342 trial,,advanced breast cancers (stage IV or inoperable),CX (paclitaxel),96.0,,145,42,response,not related to,Objective response rate was not associated with p53 status.,2262,,Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342,Harris LN;Broadwater G;Lin NU;Miron A;Schnitt SJ;Cowan D;Lara J;Bleiweiss I;Berry D;Ellis M;Hayes DF;Winer EP;Dressler L;,2006,Breast Cancer Res,8,,,17129383,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,false,false
192,BREAST,BREAST,"Cancer, NOS",France,Western Europe,Europe,More developed regions,"Hopital Saint Louis, Paris",1997-2003,noninflammatory consecutive primary cancers,CX (dose-dense epirubicin-cyclophosphamide),,,80,28,response,associated with good,"All 15 complete responses occurred among the 28 TP53-mutant tumors. Furthermore, among the TP53-mutant tumors, nine out of ten of the highly aggressive basal subtypes (defined by basal cytokeratin [KRT] immunohistochemical staining) experienced complete pathological responses, and only TP53 status and basal subtype were independent predictors of a complete response. Expression analysis identified many mutant TP53-associated genes, including CDC20, TTK, CDKN2A, and the stem cell gene PROM1, but failed to identify a transcriptional profile associated with complete responses among TP53 mutant tumors. In patients with unresponsive tumors, mutant TP53 status predicted significantly shorter overall survival. The 15 patients with responsive TP53-mutant tumors, however, had a favorable outcome, suggesting that this chemotherapy regimen can overcome the poor prognosis generally associated with mutant TP53 status.",2363,,Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen1,Bertheau P;Turpin E;Rickman DS;Espie M;de Reynies A;Feugeas JP;Plassa LF;Soliman H;Varna M;de Roquancourt A;Lehmann-Che J;Beuzard Y;Marty M;Misset JL;Janin A;de The H;,2007,PLoS Med,4,,,17388661,,,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
193,BREAST,BREAST,"Cancer, NOS","Europe, NOS","Europe, NOS",Europe,More developed regions,Various European Institutions,1987-1997,consecutive primary cancers,,78.0,1-262,1794,308,survival,associated with bad,"TP53 mutations within exons 5 to 8 conferred an elevated risk of breast cancer-specific death of 2.27 (relative risk >10 years; P < 0.0001) compared with patients with no such mutation. The prognostic value of TP53 mutation was independent of tumor size, node status, and hormone receptor content, confirming and reconciling previous findings in smaller series. Moreover, an interaction between TP53 mutation and progesterone receptor (PR) status was revealed, TP53 mutation combined with the absence of progesterone receptor being associated with the worst prognosis. Whereas previous studies have emphasized the fact that missense mutations in the DNA-binding motifs have a worse prognosis than missense mutations outside these motifs, we show that non-missense mutations have prognostic value similar to missense mutations in DNA-binding motifs. Nonetheless, specific missense mutants (codon 179 and R248W) seem to be associated with an even worse prognosis.",2369,,"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer",Olivier M;Langerod A;Carrieri P;Bergh J;Klaar S;Eyfjord J;Theillet C;Rodriguez C;Lidereau R;Bieche I;Varley J;Bignon Y;Uhrhammer N;Winqvist R;Jukkola-Vuorinen A;Niederacher D;Kato S;Ishioka C;Hainaut P;Borresen-Dale AL;,2006,Clin Cancer Res,12,1157,1167,16489069,include data from refs,,DNA,TGGE/SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
195,BREAST,BREAST,"Cancer, NOS",Norway,Northern Europe,Europe,More developed regions,Ulleval University Hospital,1990-1994,primary cases,,,-192,203,48,survival,associated with bad,"Both univariate and multivariate analysis showed that TP53 mutation status, tumor size and lymph node status were the strongest predictors of breast cancer survival for the whole group of patients. Analyses of the patients with gene expression data showed that TP53 mutation status, gene expression based classification, tumor size and lymph node status were significant predictors of survival. Breast cancer cases in the 'basal-like' and 'ERBB2+' gene expression subgroups had a very high mortality the first two years, while the 'highly proliferating luminal' cases developed the disease more slowly, showing highest mortality after 5 to 8 years. The TP53 mutation status showed strong association with the 'basal-like' and 'ERBB2+' subgroups, and tumors with mutation had a characteristic gene expression pattern.",2370,1764,TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer,Langerod A;Zhao H;Borgan O;Nesland JM;Bukholm IR;Ikdahl T;Karesen R;Borresen-Dale AL;Jeffrey SS;,2007,Breast Cancer Res,9,,,17504517,"see also ref 1764, 1863, 2369",fresh,DNA,TTGE,direct,true,true,true,true,true,true,true,true,true,true,false
211,BREAST,BREAST,"Carcinoma, NOS",Norway,Northern Europe,Europe,More developed regions,Bergen Hospitals,1997-2003,locally advanced non-inflammatory brast cancer (T3-4 and/or N2),epirubicin,,0-84,107,23,response,associated with bad,"TP53 mutations were associated with chemoresistance, defined as progressive disease on therapy (p = 0.0358; p = 0.0136 for mutations affecting p53 loop domains L2/L3). Combined mutations affecting either CHEK2 (germline) or TP53 (somatic) strongly predicted therapy resistance (p = 0.0101; TP53 mutations restricted to the L2/L3 domains: p = 0.0032).",2547,,CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer,Chrisanthar R;Knappskog S;Lokkevik E;Anker G;Ostenstad B;Lundgren S;Berge EO;Risberg T;Mjaaland I;Maehle L;Engebretsen LF;Lillehaug JR;Lonning PE;,2008,PLoS One,3,,,18725978,,frozen,DNA/RNA,none,direct/cloned,false,false,false,true,true,true,true,true,true,false,false
213,BREAST,BREAST,"Carcinoma, NOS",China,Eastern Asia,Asia,Less developed regions,"Breast Center, Peking University, School of Oncology",1994-1998,consecutive operable primary breast cancer (stage: I–III),CX/Cx-TAM/TAM/-,,0-144,414,68,survival,associated with bad,"Five year DFS and DSS were significantly lower in patients with a mutant p53 in their tumors than in those with a wild-type p53 (DFS, p=0.01; DSS, p =0.04). the P/P variant remained an independent prognostic factor of DFS among patients with a wild-type p53 tumor (HR 5 2.5; 95%CI 5 1.4–4.4; p 5 0.003). We conclude that the effect of p53 codon 72 genotype on breast cancer survival is dependent on p53 gene status, the P/P variant is strongly associated with poor prognosis among patients with a wild-type p53 tumor.",2548,,Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status,Xu Y;Yao L;Zhao A;Ouyang T;Li J;Wang T;Fan Z;Fan T;Lin B;Lu Y;Xie Y;,2008,Int J Cancer,122,2761,2766,18348141,,fixed,DNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
219,BREAST,BREAST,"Cancer, NOS",The Netherlands,Western Europe,Europe,More developed regions,Rotterdam Cancer Institute,1979-1991,,SU; tamoxifen,7.5,,202,65,survival/response,associated with bad,"TP53 mutation was significantly associated with a poor response to tamoxifen (31% versus 66%; OR, 0.22; 95% (CI), 0.12– 0.42; P < 0.0001). Patients with TP53 gene mutations in codons that directly contact DNA or with mutations in the zinc-binding domain loop L3 showed the lowest response to tamoxifen (18% and 15% response rates, respectively). In multivariate analysis for response including the classical parameters age and menopausal status, disease-free interval, dominant site of relapse, and levels of estrogen receptor and progesterone receptor, TP53 mutation was a significant predictor of poor response in the tamoxifen-treated group (OR, 0.29, 95% CI, 0.13– 0.63, P< 0.0014). TP53-mutated and estrogen receptor-negative (<10 fmol/mg protein) tumors appeared to be the most resistant phenotype. The median progression-free survival after systemic treatment was shorter for patients with a TP53 mutation than for patients with wild-type TP53 (6.6 and 0.6 months less for tamoxifen and up-front chemotherapy, respectively).",2551,1003,Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer,Berns EM;Foekens JA;Vossen R;Look MP;Devilee P;Henzen-Logmans SC;van S;van Putten WL;Inganas M;Meijer-van Gelder ME;Cornelisse C;Claassen CJ;Portengen H;Bakker B;Klijn JG;,2000,Cancer Res,60,2155,2162,10786679,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
221,BREAST,BREAST,"Cancer, NOS",USA,Northern America,Americas,More developed regions,Population based,2002-2004,,RX/CX/HT,67.0,3-89,859,128,survival,associated with bad,"Any p53 mutation and missense mutations, but not p53 protein overexpression, were associated with breast cancer-specific mortality (hazard ratio [HR] 1.7, 95% CI 1.0–2.8; HR 2.0, 95% CI 1.1–3.6, respectively) and all-cause mortality (HR 1.5, 95% CI 1.0–2.4; HR 2.0, 95% CI  1.2–3.4, respectively); nonsense mutations were associated only with breast cancer-specific mortality (HR  3.0, 95% CI 1.1–8.1). These associations however did not remain after adjusting for ER/PR status.",2560,,"Mutations in p53, p53 protein overexpression and breast cancer survival",Rossner P;Gammon MD;Zhang YJ;Terry MB;Hibshoosh H;Memeo L;Mansukhani M;Long CM;Garbowski G;Agrawal M;Kalra TS;Gaudet MM;Teitelbaum SL;Neugut AI;Santella RM;,2008,J Cell Mol Med,13,3847,3857,19602056,,fixed,DNA,Surveyor Mutation Detection Kit,direct,false,false,false,true,true,true,true,false,false,false,false
54,COLON,COLON,"Cancer, NOS",USA,Northern America,Americas,More developed regions,Utah and California centers,1991-1994,"population-based study; first-primary incident cases, aged 30-79.",,,,1464,665,survival,associated with bad,"p53 mutations were significantly more common in distal tumors (p < 0.01), tumors of relatively high stage (p = 0.04), tumors without MSI (p < 0.01) and tumors without Ki-ras mutations (p < 0.01). In a univariate analysis, tumors with p53 mutations were associated with a significantly worse 5-year survival than those with wild-type p53 (53.4% vs. 58.8%, p = 0.04); significantly worse prognosis also was seen with missense mutations, transitions, transversions, mutations affecting the structure of the p53 molecule, mutations within the beta-sandwich motif and mutations in proximal tumors. In multivariate analyses, however, the only significant predictors of poor prognosis were G245 hot spot mutations (HRR = 2.16, 95% CI 1.06-4.40) and p53 mutations in proximal tumors (HRR = 1.34, 95% CI 1.07-1.63). We conclude that overall p53 mutational status is not an independent predictor of poor prognosis in colon cancer. However, specific classes of mutations, namely, the G245 hot spot mutation and mutations in proximal tumors, are related to significantly worse survival even after adjusting for age and stage.",1652,,Prognostic significance of p53 mutations in colon cancer at the population level,Samowitz WS;Curtin K;Ma KN;Edwards S;Schaffer D;Leppert MF;Slattery ML;,2002,Int J Cancer,99,597,602,11992552,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
61,COLON,COLON,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"Rhode Island Hospital, Providence",1983-1988,"consecutive primary cancers; stage 3 (Dukes' C, T3)",SU,96.0,0-84,70,43,survival,associated with bad,"Five-year survival was 75% in patients with nonmutated lesions, significantly lower (21%) with TP53 mutations (P = 0.01), and intermediate with K-ras-2 only (45%) or both K-ras-2 and TP53 mutations (36%). A TP53 mutation carried the highest relative risk of death (2.39; 95% confidence interval, 1.29 to 4.42; P = 0.006). There was an additive effect on the risk of death between TP53 mutations and adverse histopathologic features.",1658,,Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon,Pricolo VE;Finkelstein SD;Wu TT;Keller G;Bakker A;Swalsky PA;Bland KI;,1996,Am J Surg,171,41,46,8554149,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
17,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Singapore,South Eastern Asia,Asia,Less developed regions,Singapore General Hospital,,consecutive single ADC,"SU, RX/CX in 54 patients",24.0,0-60,192,109,survival,associated with bad,"We found that patients with tumors harboring mutated p53 genes showed a significantly poorer prognosis than did those patients with genes without point mutations, and, moreover, patient response to postoperative therapies depended significantly on mutation status in both adjuvant and palliative treatment cohorts. However, not all point mutations were the same functionally; point mutations within the conserved domains of the p53 tumor suppressor gene were inherently more aggressive than tumors with point mutations outside of these domains, and mutations of codon 175 were particularly aggressive.",555,,P53 point mutation and survival in colorectal cancer patients,Goh HS;Yao J;Smith DR;,1995,Cancer Res,55,5217,5221,0007585578,,,DNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
62,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",USA,Northern America,Americas,More developed regions,Johns Hopkins Hospital,1983-1987,,SU,,0-72,46,19,survival,not related to,"There was a higher survival rate independent of Dukes' stage in the group with no alterations in p53 compared with those with evidence of dysfunction of p53, but the difference was not statistically significant.",708,,Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma,Slebos RJ;Baas IO;Clement M;Polak M;Mulder JW;van den Berg FM;Hamilton SR;Offerhaus GJ;,1996,Br J Cancer,74,165,171,0008688317,,fixed,DNA,DGGE,cloned,false,false,false,true,true,true,true,false,false,false,false
16,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Norway,Northern Europe,Europe,More developed regions,Hospitals in Oslo region,1987-1989,consecutive primary cancers,SU,56.8,0.5-92.2,222,102,survival,associated with bad,"Presence of a TP53 mutation was also significantly associated with absence of microsatellite instability (P = 0.028), as well as with loss of heterozygosity at 17p13 (P < 0.001). The TP53 mutations in the left-sided and rectal tumors were more often transversions than transitions, indicating a different etiology in the development of these tumors. The tendency for shorter cancer-related survival among patients with mutations in their tumors was only statistically significant for patients with left-sided tumors (P = 0.003). All patients with mutations affecting the L3 domain of the protein involved in zinc binding had a significantly shorter cancer-related survival (P = 0.036), indicating that mutations affecting this domain have biological relevance in terms of colorectal cancer disease course. Follow-up study published in J Clin Oncol. 2003 Mar 1;21(5):820-9 confirmed a significant association between mutations affecting the L3 zinc-binding domain of TP53 and survival in this cohort after 10 years of follow-up, and also was found to apply for patients in the Dukes' B group.",918,918,TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival,Borresen-Dale AL;Lothe RA;Meling GI;Hainaut P;Rognum TO;Skovlund E;,1998,Clin Cancer Res,4,203,210,0009516972,Prevalence in ref 2131,fixed,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
170,"COLORECTUM, NOS","COLORECTUM, NOS","Adenocarcinoma, NOS",Spain,Southern Europe,Europe,More developed regions,"San Carlos Hospital, Madrid",1990-1993,,,,1-70,61,18,survival,associated with bad,"Kaplan-Meier survival curves suggested that patients bearing a TP53 mutation had a shorter survival compared to those without p53 mutations: this difference turned out not to be statistically significant (p=0,40). When we performed univariate survival analysis of the function of affected exons, patients bearing p53 mutations in exon 7 had a statistically significantly poorer clinical evolution, as compared to those patients without underlying p53 mutations (p=0,02).",1021,797,p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer,Iniesta P;Vega FJ;Caldes T;Massa M;de Juan C;Cerdan FJ;Sanchez A;Lopez JA;Torres AJ;Balibrea JL;Benito M;,1998,Cancer Lett,130,153,160,0009751268,See also ref 917,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
13,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Australia,Australia/New Zealand,Western Pacific,More developed regions,"Charles Gairdner, Perth",1985-1997,retrospective study,"SU, CX (5FU; levamisole)",102.0,33-178,765,289,survival,not related to,TP53 gene mutation had no prognostic value in the overall series or in different site or stage subgroups. None of the different types of TP53 gene mutation showed prognostic value.,1424,,"Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation",Soong R;Powell B;Elsaleh H;Gnanasampanthan G;Smith DR;Goh HS;Joseph D;Iacopetta B;,2000,Eur J Cancer,36,2053,2060,11044641,,,DNA,SSCP,direct,false,false,true,true,true,true,true,true,true,false,false
19,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",The Netherlands,Western Europe,Europe,More developed regions,University Hospital Groningen,1991-1993,consecutive primary cancers,"SU, CX (5FU)",47.0,32-66,55,24,survival,not related to,"Cancer-specific survival did not differ significantly between patients with K-ras or TP53 or both mutated and nonmutated tumors, respectively (log-rank test: K-ras, P = 0.72 and TP53, P = 0.77; K-ras and TP53, P = 0.8).",1524,1252,Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer,Bleeker WA;Hayes VM;Karrenbeld A;Hofstra RM;Verlind E;Hermans J;Poppema S;Buys CH;Plukker JT;,2001,Dis Colon Rectum,44,358,363,11289281,,fixed,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
30,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",France,Western Europe,Europe,More developed regions,Multicenter study,1994-1996,liver metastasis from CRC; prospective study,"SU, CX (5FU)",18.7,0-60,56,35,response,not related to,No significant association was found between response to chemotherapy and p53 mutations (78% mutated tumors in responders vs. 55% in nonresponders; p = 0.10) and K-ras mutations (39% mutated tumors in responders vs. 26% in nonresponders; p = 0.34). Survival was longer for patients with p53-mutated metastases than for patients with unresected wild-type p53 metastases (median survival 15 months vs. 17 months; p = 0.06).,1540,1540,"Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival",Rosty C;Chazal M;Etienne MC;Letoublon C;Bourgeon A;Delpero JR;Pezet D;Beaune P;Laurent-Puig P;Milano G;,2001,Int J Cancer,95,162,167,11307149,,frozen,DNA,DGGE,direct,false,false,true,true,true,true,true,true,false,false,false
15,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Sweden,Northern Europe,Europe,More developed regions,"University Hospital, Umea",1988-1992,consecutive primary cancers,"SU, pre-op RX in 28 RC",,0-106,189,99,survival,associated with bad,"There was a significant relationship between the p53 mutational status and the cancer-specific survival time, with shorter survival time for patients who had p53 mutations than for those who did not (P = .01, log-rank test). Mutations outside the evolutionarily conserved regions were associated with the worst prognosis. Multivariate analysis showed that the presence of p53 mutations was an independent prognostic factor (relative hazard, 1.7, P = .03).",1644,,Prognostic value of p53 genetic changes in colorectal cancer,Kressner U;Inganas M;Byding S;Blikstad I;Pahlman L;Glimelius B;Lindmark G;,1999,J Clin Oncol,17,593,599,10080604,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
18,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",USA,Northern America,Americas,More developed regions,"University of Texas Health Science Center, San Antonio",1993-1995,consecutive primary cancers; prospective study,SU,45.0,3-72,56,28,survival,associated with bad,"Overall 4-year survival rates for patients with wild-type p53 and mutant p53 were 71% and 54%, respectively (P = 0.05). The 4-year disease free survival rates for patients with wild-type p53 and mutant p53 were 83% and 62%, respectively (P = 0.09). p53 status and stage were found to be independent significant predictors for survival (p53 negative: P = 0. 02; stage: P = 0.0002.)",1645,,p53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma,Kahlenberg MS;Stoler DL;Rodriguez-Bigas MA;Weber TK;Driscoll DL;Anderson GR;Petrelli NJ;,2000,Cancer,88,1814,1819,10760757,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
35,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Spain,Southern Europe,Europe,More developed regions,"Hospital de Sant Pau, Barcelona",1991-1993,consecutive primary cancers; prospective study,"SU, CX and/or RX for 32 patients",,0-60,132,66,survival,not related to,"Multivariate analysis of the whole population analyzed (n = 132) showed that survival was strongly correlated with the presence of p53 mutations alone or in combination with K-ras mutations (P = .002; log-rank test). When only patients undergoing a radical resection were considered (R0; n = 101), p53 mutations were no longer of prognostic significance.",1649,1649,p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer,Tortola S;Marcuello E;Gonzalez I;Reyes G;Arribas R;Aiza G;Sancho FJ;Peinado MA;Capella G;,1999,J Clin Oncol,17,1375,1381,10334521,,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,false,false,false
36,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Japan,Eastern Asia,Asia,More developed regions,"Nihon University School of Medecine, Tokyo",1989-1997,consecutive primary cancers,"SU, CX (5FU) for a few patients",65.0,38-136,106,39,survival,associated with bad,"The cases without p53 mutation showed significantly improved prognosis compared to the cases with p53 mutation (p = 0.0085). In distal tumors, Dukes' stage, liver metastasis, p53 mutation and p53 protein overexpression were significant predictors of survival. Multivariate analysis of all tumors, p53 mutation and liver metastasis were independent indicators of poor survival (p = 0.0223 for p53 mutation, p = 0.0254 for liver metastasis). Also in distal tumors, p53 mutation was an independent indicator (p = 0.0011). Furthermore, the relative risk associated with p53 mutation in distal tumors was much higher than that in all tumors (8.260 vs. 1.796). In proximal tumors, p53 mutation was not an independent indicator (p = 0.6673)",1650,,p53 mutation found to be a significant prognostic indicator in distal colorectal cancer,Okubo R;Masuda H;Nemoto N;,2001,Oncol Rep,8,509,514,11295071,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
70,"COLORECTUM, NOS","COLORECTUM, NOS","Adenocarcinoma, NOS",UK,Northern Europe,Europe,More developed regions,"Chelsea & Westminster Hospital, London",,Coloretal liver metastasis treated with hepatic arterial chemotherapy (floxuridine).,CX (floxuridine),,,28,21,survival/response,not related to,"There was a significantly lower prevalence (Fisher's, P=0.001) of patients with p53 ""hot spot""-mutated liver metastases in stable disease and partial response (5/22) than in progressive (6/6) disease groups. Significantly fewer (Mann-Whitney U, P=0.002) p53 ""hot spot"" mutations/biopsy were observed in liver metastases from stable disease and partial response (median 0, iqr. 0-0) than in progressive (median 1, iqr 1-2) disease patients. p53 ""Hot spot""-mutated liver metastases were associated with significantly shorter survival times (logrank P=0.05) after hepatic arterial floxuridine. Significant response or survival-time differences by total or L2/L3 zinc-binding site p53 mutations were not detected.",1681,1402,P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases,Khan ZA;Jonas SK;Feldmann KA;Patel H;Wharton RQ;Tarragona A;Ivison A;Allen-Mersh TG;,2001,J Cancer Res Clin Oncol,127,675,680,11710597,,frozen,RNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
97,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Japan,Eastern Asia,Asia,More developed regions,Nagasaki University School of Medecine,1997-1998,,"SU, CX (5FU)",33.0,4-55,79,58,survival,associated with bad,"In another group of 79 cases of colorectal cancer analyzed for p53 gene mutation by using NIRCA, mutations were detected in 58 of 79 (73.4%) cases. Multivariate Cox proportional-hazards analysis showed that p53 gene mutation was a significant prognostic factor in patients with colorectal cancer.",1826,,Detection of p53 gene mutations by nonisotopic RNase cleavage assay as a predictor of poor prognosis in colorectal cancers,Haseba M;Hidaka S;Tsuji T;Yano H;Komatsu H;Sawai T;Yasutake T;Nakagoe T;Tagawa Y;Ayabe H;,2003,Dig Dis Sci,48,1984,1989,14627345,,,RNA,NIRCA,,false,false,false,true,true,true,true,true,false,false,false
108,"COLORECTUM, NOS","COLORECTUM, NOS","Adenocarcinoma, NOS",Chinese Taipei (Taiwan),South Eastern Asia,Asia,Less developed regions,Chang Gung Memorial Hospital,1992-1993,consecutive primary cancers,"SU, CX (5FU)",,6-135,138,51,recurrence,associated with bad,"P53 gene was not a prognostic factor among patients receiving post-operative 5-FU-based adjuvant therapy (PAT), whereas its mutation was associated with a poorer prognosis in stage II–III colorectal (hazard ratio (HR)=3.1, 95% confidence interval, 0.9-11.0) among patients without PAT. Our data confirmed that p53 mutation is an independent pre-treatment factor in stage II and III colorectal cancer after curative resection. p53 is not only a risk marker but also an effect modifier of effectiveness of PAT among patients with TNM stage II–III colorectal cancer.",1932,1548,p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy,Tang R;Wang JY;Fan CW;Tsao KC;Chen HH;Wu CM;Chen JS;Changchien CR;Hsieh LL;,2004,Cancer Lett,210,101,109,15172127,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
124,"COLORECTUM, NOS","COLORECTUM, NOS","Carcinoma, NOS",China,Eastern Asia,Asia,Less developed regions,"Taipei Veterans General Hospital, Taipei, Taiwan",1999-2000,"sporadic CRC, no oreoperative chemotherapy, no emergent operative procedure, no death within 30 postoperative days",SU,,1-50,213,96,survival,associated with bad,"According to multivariate analysis, tumor stage and p53 mutation were significantly associated with disease progression. Patients with p53 mutations had 4-year disease-free survival (DFS) and 4-year OS of 43% and 62%, respectively, while patients whose tumors had no p53 mutation had DFS and OS rates of 67% and 80%, respectively. The 4-year disease-free survival (DFS) of patients with MSS-diploid, wild-type p53 tumors was 67% and significantly higher than those of patients with MSS-diploid, mutant p53 CRC (30%, p = 0.003). The same trend was found in patients with MSS-aneuploid CRC(wild p53 vs. mutant p53, 64% vs. 41%, p = 0.009). We concluded that CIN, MSI and p53 mutation status might be used as a multiple parameter profile for the prognosis of sporadic colorectal cancer.",2083,,Relationship between genetic alterations and prognosis in sporadic colorectal cancer,Chang SC;Lin JK;Yang SH;Wang HS;Li AF;Chi CW;,2006,Int J Cancer,118,1721,1727,16231316,,frozen,DNA,none,direct,false,false,false,true,true,true,true,true,false,false,false
134,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",The Netherlands,Western Europe,Europe,More developed regions,University Medical Center Groningen,,colorectal liver metastasis eligible for liver surgery,,,,44,20,recurrence/survival,not related to,"The 5-year actual survival was not influenced by TP53 mutational status. In patients with surgically treated colorectal liver metastases, TP53 mutations and angiogenic status did not influence prognosis.",2102,,"P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression",de Jong KP;Gouw AS;Peeters PM;Bulthuis M;Menkema L;Porte RJ;Slooff MJ;van Goor H;Van den BA;,2005,Clin Cancer Res,11,4067,4073,15930341,,fixed/frozen,DNA,DGGE,direct,true,true,true,true,true,true,true,true,true,true,false
157,"COLORECTUM, NOS","COLORECTUM, NOS","Adenocarcinoma, NOS",Italy,Southern Europe,Europe,More developed regions,"Department of Oncology, University of Palermo",1988-1992,primary untreated cancer,SU,71.0,34-115,160,68,survival,associated with bad,"Specific TP53 mutations in L3 domain alone (only in Disease Free Survival), or in combination with specific Ki-ras mutations at codon 13, are associated with a worse prognosis in sporadic CRC.",2179,,Molecular pathological subclassification of mucinous adenocarcinoma of the colorectum,Li D;Semba S;Wu M;Yokozaki H;,2005,Pathol Int,55,766,774,16287491,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
162,"COLORECTUM, NOS","COLORECTUM, NOS","Carcinoma, NOS",Italy,Southern Europe,Europe,More developed regions,"Department of Oncology, University of Palermo",1988-1992,"electively resected primary CRC, available DNA from normal & tumor tissue, none chemotherapy or radiation therapy before surgery, no family history",,71.0,34-115,160,58,recurrence/survival,associated with bad,"At univariate analysis, the presence (p<0,01), type (frameshift -p<0,05-) or site (in conserved regions, affecting L3 -p<0,05-) of p53 mutations proved to be significantly related to quicker relapse, whereas they were significantly related to shorter OS (p<0,01, p<0,05, p<0,01 respectively).",2186,1108,"p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up",Russo A;Migliavacca M;Zanna I;Valerio MR;Latteri MA;Grassi N;Pantuso G;Salerno S;Dardanoni G;Albanese I;La Farina M;Tomasino RM;Gebbia N;Bazan V;,2002,Cancer Epidemiol Biomarkers Prev,11,1322,1331,12433709,See also ref 1963 and 1964,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
163,"COLORECTUM, NOS","COLORECTUM, NOS","Carcinoma, NOS",UK,Northern Europe,Europe,More developed regions,"Ninewells Hospital, Dundee and Perth Royal Infirmary",1997-1999,"Caucasian patients, with primary cancer, undergoing surgery",,,,107,65,survival,not related to,"Neither p53 or APC was found to affect prognosis (p=0,8290 and p=0,9034, respectively). In contrast, K-ras mutations were significantly associated with poor patient prognosis (p=0,0098).",2196,1725,"The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma",Conlin A;Smith G;Carey FA;Wolf CR;Steele RJ;,2005,Gut,54,1283,1286,15843421,,frozen,DNA,DHPLC,direct,true,true,true,true,true,true,true,true,true,true,false
164,"COLORECTUM, NOS","COLORECTUM, NOS","Carcinoma, NOS",Finland,Northern Europe,Europe,More developed regions,,1994-1998,C-Dukes stages treated by surgery only,SU,,,46,25,survival,not related to,No differences in survival were observed in patients whose tumors had a mutant or wild-type p53 gene.,2197,,Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer,Arango D;Laiho P;Kokko A;Alhopuro P;Sammalkorpi H;Salovaara R;Nicorici D;Hautaniemi S;Alazzouzi H;Mecklin JP;Jarvinen H;Hemminki A;Astola J;Schwartz S Jr;Aaltonen LA;,2005,Gastroenterology,129,874,884,16143127,,frozen,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
167,"COLORECTUM, NOS","COLORECTUM, NOS","Carcinoma, NOS",NA,NA,NA,NA,"164 sites in USA, Australia, New Zealand",2000-2002,"metastatic colorectal carcinoma, at least 18 years, life expectancy more than 3 months, untreated","CX (irinotecan, FU, leucovirin +/- bevacizumab)",,,227,154,survival/response,not related to,"We did not observe a statistically significant difference in the survival benefit conferred by the addition of bevacizumab for patients with p53 mutant tumors compared with patients with p53 wt tumors. Similarly, neither p53 mutation nor p53 overexpression was satistically associated with the overall survival with metastatic colorectal cancers.",2217,,"Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab",Ince WL;Jubb AM;Holden SN;Holmgren EB;Tobin P;Sridhar M;Hurwitz HI;Kabbinavar F;Novotny WF;Hillan KJ;Koeppen H;,2005,J Natl Cancer Inst,97,981,989,15998951,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
182,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",Japan,Eastern Asia,Asia,More developed regions,"Department of Digestive and General Surgery, Saitama Medical School",2002-2003,"Histologically proven CRC with at least 1 metastasis, no prior treatment during the preceding 4 weeks",CX (5-FU/Leucovorin),,,33,25,survival/response,not related to,"There was no relationship between p53 mutation alone and clinical outcome, such as response or survival (data not shown). However, in p53 mutant-type tumors, those with low FDXR gene expression had statistically significantly worse survival than those with high FDXR gene expression.",2282,,Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin,Ichikawa W;Ooyama A;Toda E;Sugimoto Y;Oka T;Takahashi T;Shimizu M;Sasaki Y;Hirayama R;,2006,Cancer Chemother Pharmacol,58,794,801,16528528,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
196,"COLORECTUM, NOS","COLORECTUM, NOS","Adenocarcinoma, NOS",Turkey,Western Asia,Asia,Less developed regions,Marmara University Hospital,1990-2002,sporadic CRC surgically resected,,76.0,6-168,43,14,survival,not related to,Neither the Kras mutations nor the p53 aberrations correlated with prognosis.,2390,,"Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers",Akkiprik M;taizi-Celikel C;Dusunceli F;Sonmez O;Gulluoglu BM;Sav A;Ozer A;,2007,J Gastrointestin Liver Dis,16,11,17,17410283,,,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
197,"COLORECTUM, NOS","COLORECTUM, NOS","Cancer, NOS",France,Western Europe,Europe,More developed regions,Multicenter study,1994-1998,liver metastasis from CRC,"SU, CX (5FU, folinic acid)",52.8,,97,55,survival,associated with bad,"Univariate Cox analyses demonstrated that p53 stop mutation in metastasis (risk of death of stop mutations v wild type, 3.14; P =.018) was a significant biologic predictor of specific survival.",2395,1540,Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses,Etienne MC;Chazal M;Laurent-Puig P;Magne N;Rosty C;Formento JL;Francoual M;Formento P;Renee N;Chamorey E;Bourgeon A;Seitz JF;Delpero JR;Letoublon C;Pezet D;Milano G;,2002,J Clin Oncol,20,2832,2843,12065560,,frozen,DNA,DGGE,direct,false,false,true,true,true,true,true,true,false,false,false
138,CORPUS UTERI,CORPUS UTERI,"Carcinoma, NOS","More developed regions,NOS","More developed regions,NOS","More developed regions,NOS",More developed regions,"Dep. Of Obstetrics abd Gynecology, Mainz University, Germany",1990-2000,,,58.0,1-130,92,24,survival,associated with bad,"The patients with dominant-negative mutation had significantly shorter survival than patients with no mutation (p < 0.0001) and those with a recessive mutation (p = 0.01) in the p53 gene. No difference in survival was found between the patients with tumors harboring a recessive p53 mutation and those with tumors harboring a wild-type p53. Multivariate analysis revealed that dominant-negative p53 mutation (p = 0.019), FIGO stage (p = 0.0037) and histologic subtype (p = 0.014) were independently related to patient survival. Dominant-negative p53 mutation was the most important prognostic factor for stage III/IV endometrial cancer (p = 0.0023). In conclusion, dominant-negative p53 mutation is often found in advanced stages and aggressive histologic subtypes of endometrial cancer and it is a strong predictor of survival of patients with advanced endometrial cancer.",2133,1687,Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer,Sakuragi N;Watari H;Ebina Y;Yamamoto R;Steiner E;Koelbl H;Yano M;Tada M;Moriuchi T;,2005,Int J Cancer,116,514,519,15825182,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
140,CORPUS UTERI,CORPUS UTERI,"Endometrioid adenocarcinoma, NOS",USA,Northern America,Americas,More developed regions,"University of Southern California School of Medicine, Los Angeles, California",1980-1989,primary cases,"SU, RX for 22 cases",,3-120,59,12,survival,associated with bad,Women harboring either a mutation or an Arg/Pro allelotype at codon 72 had a lower overall survival rate than women whose tumors lacked alterations in the p53 gene (P= 0.0029). Women with p53 genetic alterations who did not receive adjuvant radiotherapy had the lowest survival rate (P= 0.0005). (+ trend toward none relation with treatment response),2134,,Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas,Saffari B;Bernstein L;Hong DC;Sullivan-Halley J;Runnebaum IB;Grill HJ;Jones LA;el Naggar A;Press MF;,2005,Int J Gynecol Cancer,15,952,963,16174251,,frozen,DNA,SSCP/IHC,direct,true,true,true,true,true,true,true,true,true,true,false
215,CORPUS UTERI,CORPUS UTERI,"Endometrioid adenocarcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Yamaguchi University Graduate School of Medicine,,surgically resected cases,"SU, ?",35.0,3-89,104,21,survival,not related to,p53 mutation correlates with aneuploidy and CIN but not patient outcomes.,2550,,Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation,Suehiro Y;Okada T;Okada T;Anno K;Okayama N;Ueno K;Hiura M;Nakamura M;Kondo T;Oga A;Kawauchi S;Hirabayashi K;Numa F;Ito T;Saito T;Sasaki K;Hinoda Y;,2008,Clin Cancer Res,14,3354,3361,18519763,,frozen,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
40,ESOPHAGUS,ESOPHAGUS,"Squamous cell carcinoma, NOS","China, Hong-Kong",Eastern Asia,Asia,More developed regions,Queen Mary Hospital,1990-1994,consecutive primary cancers,SU,12.0,,70,31,survival,associated with bad,"In patients with stage III oesophageal cancer, the median survival of those with p53 mutations was 6.8 months whereas those without was 12.5 months. The results were of clinical importance although the value did not reach statistical significance.",809,,Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: a prospective clinico- pathological study and survival analysis of 70 patients,Lam KY;Tsao SW;Zhang D;Law S;He D;Ma L;Wong J;,1997,Int J Cancer,74,212,219,0009133458,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
26,ESOPHAGUS,ESOPHAGUS,"Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,"Kurume University School of Medecine, Hokkaido,",1989-1996,consecutive primary cancers,"SU, CX/RX",28.0,1-104,138,78,survival/response,associated with bad,"We detected p53 mutations in the tumors of 78 (56.5%) patients. Kaplan-Meier analysis showed that these 78 patients tended to have shorter survival times and greater resistance to either form of therapy than patients whose tumors carried two wild-type p53 alleles. The difference became more evident when we focused on mutations in zinc-binding domains of p53 (L2 and L3); the prognosis was significantly poorer among the 29 patients with tumors in this category than among patients whose tumors had no p53 mutations, or p53 mutations outside L2 or L3 (P=0.0060). Moreover, those tumors as a group were more resistant to chemotherapy or radiation than the others (P=0.0105).",1352,,Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients,Kihara C;Seki T;Furukawa Y;Yamana H;Kimura Y;van Schaardenburgh P;Hirata K;Nakamura Y;,2000,Jpn J Cancer Res,91,190,198,0010761706,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
79,ESOPHAGUS,ESOPHAGUS,"Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Osaka City University Medical School; Osaka City General Hospital,1993-1998,consecutive primary cancers,SU; CX (?),28.0,3-88,57,43,survival,not related to,"Survival rate after surgery was not significantly associated with the presence of p53 gene mutation. However, in the Young Group with p53 gene mutation, those who had null mutations had a significantly shorter survival than those without null mutations (P = 0.0455). No other clinicopathological factors were associated with p53 gene mutations.",1489,,Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group,Okuda E;Osugi H;Morimura K;Takada N;Takemura M;Fukushima S;Higashino M;Kinoshita H;,2001,Clin Cancer Res,7,600,606,11297255,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
37,ESOPHAGUS,ESOPHAGUS,"Adenocarcinoma, NOS",Germany,Western Europe,Europe,More developed regions,"Technische Universitat Munchen, Munich",,prospective study; Barrett's carcinoma,SU,44.1,0-96,49,21,survival,associated with bad,The presence of a p53 mutation in the tumor had a significant impact on survival after curative resections (RO-resections) with cumulative 5-year survival probabilities of 68.8+/-9.7% for mutation-negative tumors and 24.3+/-9.9% for mutation-positive tumors (log rank: P < 0.001).,1651,,P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus,Schneider PM;Stoeltzing O;Roth JA;Hoelscher AH;Wegerer S;Mizumoto S;Becker K;Dittler HJ;Fink U;Siewert JR;,2000,Clin Cancer Res,6,3153,3158,10955797,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
94,ESOPHAGUS,ESOPHAGUS,"Carcinoma, NOS",USA,Northern America,Americas,More developed regions,The Sidney Kimmel Comprehensive Center at John Hopkins,,,"SU, RX, CX (5FU, CP)",,0-133,46,29,survival,associated with good,"The OS was 43% at 5 years. Presence of CR (P < 0.001 log rank) and p53 mutation (P = 0.051 log rank) correlated with increased OS, whereas increased EGF-R expression predicted poor OS (P = 0.009 log rank). EGF-R remained significant when adjusted for clinical covariates. There was a trend toward increased OS related to better tumor differentiation and decreased bcl-2. CONCLUSIONS: These data suggest that EGF-R and p53 mutation may be used as both outcome predictors and targets for molecular therapy for esophageal cancer.",1823,,"Epidermal Growth Factor Receptor, p53 Mutation, and Pathological Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Preoperative Chemoradiotherapy",Gibson MK;Abraham SC;Wu TT;Burtness B;Heitmiller RF;Heath E;Forastiere A;,2003,Clin Cancer Res,9,6461,6468,14695149,Data provided by Gibson,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
106,ESOPHAGUS,ESOPHAGUS,"Adenocarcinoma, NOS",Canada,Northern America,Americas,More developed regions,Dalhousie University,1991-2001,consecutive primary cancers,SU,,,91,46,survival,not related to,"A total of 57.1% (n = 52) of tumors had p53 alterations (mutations and/or protein overexpression), which on univariate analysis were associated with poor tumor differentiation (P =.001), advanced pTNM stage (P =.009), and number of involved lymph nodes (0, 1-3, >3; P =.04). Patients with p53 alterations had significantly reduced 5-year overall survival relative to patients with wild-type p53 (15% vs 46%; P =.004).",1836,733,Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study,Casson AG;Evans SC;Gillis A;Porter GA;Veugelers P;Darnton SJ;Guernsey DL;Hainaut P;,2003,J Thorac Cardiovasc Surg,125,1121,1131,12771886,See also ref 1036,,DNA,SSCP,direct,false,false,true,true,true,true,true,true,true,false,false
159,ESOPHAGUS,ESOPHAGUS,"Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Chiba University Hospital,1986-1993,"primary SCC stage II or III, N0",SU,,0-60,42,14,survival,associated with bad,"The 5-year survival rate of the p53 mutation(-) group (n = 28) was significantly higher than the (+) group (n = 14; 51.0% versus 35.7%, P <0.05 by the log rank test). Recurrence could be identified in 10 of 14 p53 mutation(+) cases (71.4%), whereas it was found in 12 of 28 (-) cases (42.8%). CONCLUSION: The current study indicated that p53 mutation of tumor tissues might be a prognostic factor for esophageal squamous cell carcinoma cases and one of the risk factors for its recurrence.",2178,,The p53 gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability,Kobayashi S;Koide Y;Endo M;Isono K;Ochiai T;,1999,Am J Surg,177,497,502,10414702,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
165,ESOPHAGUS,ESOPHAGUS,"Squamous cell carcinoma, NOS",Chinese Taipei (Taiwan),South Eastern Asia,Asia,Less developed regions,Kaohsiung Veterans General Hospital,2000-2003,consecutive primary cancers,SU,15.0,4-48,40,21,survival,not related to,"p53 mutation was not a prognostic factor p21 overexpression significantly compromised the survival of patients with mutated p53 gene (p = 0.035). However, no significant dismal effect of p21 overexpression can be seen in patients with wild-type p53 gene (p = 0.175).",2208,2204,Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients,Goan YG;Hsu HK;Chang HC;Chou YP;Chiang KH;Cheng JT;,2005,Ann Thorac Surg,80,1007,1016,16122475,,fixed/frozen,DNA/RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
223,GALLBLADDER,GALLBLADDER,"Cancer, NOS",Austria,Western Europe,Europe,More developed regions,University of Vienna,1991-2002,consecutive cancers,various,64.3,0.3-83.6,61,18,survival,not related to,After resection chemotherapy increased survival in those having a normal p53 gene compared to those having a mutation (p=0.008). p53 status did not show an influence in resected patients without chemotherapy or in palliative-treated patients regardless of their therapy.,1927,,p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry,Puhalla H;Kandioler D;Ludwig C;Filipits M;Wrba F;Laengle F;Jakesz R;Gruenberger T;,2004,Anticancer Res,24,1201,1206,15154647,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,false,false
50,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Germany,Western Europe,Europe,More developed regions,University of Heidelberg,,consecutive primary cancers,,,0-80,86,39,survival,associated with bad,"In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test). The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test).",1076,1076,TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer,Erber R;Conradt C;Homann N;Enders C;Finckh M;Dietz A;Weidauer H;Bosch FX;,1998,Oncogene,16,1671,1679,0009582015,See also ref 2347,frozen/fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
31,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",France,Western Europe,Europe,More developed regions,"Hopital Tenon, Paris",1992-1995,consecutive primary cancers,CX (5FU;CISP),,,105,40,response,associated with bad,"p53 mutation was the only variable to significantly predict objective response (odds ratio, 0. 23; 95% confidence interval, 0.10 to 0.57; P =.002) and was the strongest predictor of major response (odds ratio, 0.29; 95% confidence interval, 0.11 to 0.74; P =.006). Specific mutations (contact mutations) accounted for much of the reduction in the risk of major response associated with overall mutations.",1318,,p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck,Temam S;Flahault A;Perie S;Monceaux G;Coulet F;Callard P;Bernaudin JF;St Guily JL;Fouret P;,2000,J Clin Oncol,18,385,394,0010637254,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
32,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",France,Western Europe,Europe,More developed regions,"Laennec Hospital, Paris",1996-1997,consecutive primary cancers; prospective study,CX (5FU;CISP),,,106,72,response,associated with bad,"The prevalence of p53-mutated tumors was higher in the group of patients with nonresponse to neoadjuvant chemotherapy than in the group of responders (81% v 61%, respectively; P <.04). When compiling p53 mutations and anti-p53 antibodies in plasma, the correlation between p53 status and response to chemotherapy was significant (87% v 57%, respectively; P =.003). A multivariate analysis showed that p53 status is an independent predictive factor of response to chemotherapy.",1319,,p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series,Cabelguenne A;Blons H;de W;Carnot F;Houllier AM;Soussi T;Brasnu D;Beaune P;Laccourreye O;Laurent-Puig P;,2000,J Clin Oncol,18,1465,1473,0010735894,Add info from Beaune,frozen,DNA,DGGE,direct,false,false,true,true,true,true,true,true,false,false,false
43,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Kumamoto University Hospital,1992-1997,consecutive primary cancers,"SU, RX",,,38,23,survival,associated with bad,"Radiation sensitivity was examined by comparing tumor size on magnetic resonance images before and after completion of therapy with 45 Gy radiation, in the 18 cases of T2 oropharyngeal SCC that were initially treated by radiotherapy. The results showed that tumors with wild-type p53 decreased in size significantly compared to those with mutant p53. In 33 patients treated with curative intent, the overall survival after the completion of therapy was better in patients with a wild-type p53 tumor than in patients with a mutant p53 tumor.",1347,,Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx,Obata A;Eura M;Sasaki J;Saya H;Chikamatsu K;Tada M;Iggo RD;Yumoto E;,2000,Int J Cancer,89,187,193,0010754498,,fresh,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
27,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Denmark,Northern Europe,Europe,More developed regions,Aarhus University Hospital,1992-1996,consecutive primary cancers; retrospective study,"SU, RX",,0-60,114,45,survival,associated with bad,"TP53 mutation was highly associated with poor prognosis. Loco-regional control rates (5-year actuarial values) for TP53 mutation was 29 vs. 54% for TP53 wildtype (P < 0.01). For disease-free survival the corresponding values were 13 and 38% (P < 0.01), respectively. The correlations were not found to be related to specific subtypes of mutations (e.g. missense mutations affecting DNA-contact or Zn-binding regions).",1484,,"TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck",Alsner J;Sorensen SB;Overgaard J;,2001,Radiother Oncol,59,179,185,11325447,,fixed,DNA,DGGE,direct,false,false,false,true,true,true,true,true,false,false,false
83,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,"Hokkaido University Dental Hospital, Sapporo",1990-2000,consecutive primary cancers previously untreated,,36.0,4-139,121,51,survival,associated with bad,"Mutation of p53 was not associated with any clinicopathological parameters; however, tumors containing specific p53 mutations, e.g. DNA-binding surface regions (L2, L3 and the LSH motif) and conserved regions (II-V), had significantly poorer prognoses than tumors with mutations outside of those regions. Moreover, locoregional failure, lymph node metastasis and the occurrence of subsequent distant metastasis were also significantly associated with mutations within DNA-binding surface regions.",1779,,Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma,Yamazaki Y;Chiba I;Hirai A;Sugiura C;Notani K;Kashiwazaki H;Tei K;Totsuka Y;Fukuda H;,2003,Oral Oncol,39,163,169,12509970,,frozen,DNA/RNA,SSCP/FASAY,direct/cloned,false,false,true,true,true,true,true,true,true,false,false
90,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Italy,Southern Europe,Europe,More developed regions,Cuneo General Hospital,,"locally advanced carcinomas, TNM III/IV",,,,70,40,survival/response,associated with bad,"Clinical response following cisplatin-based chemo-radiotherapy for advanced head and neck cancer is influenced by this polymorphism, cancers expressing 72R mutants having lower response rates than those expressing 72P mutants.",1817,,p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis,Bergamaschi D;Gasco M;Hiller L;Sullivan A;Syed N;Trigiante G;Yulug I;Merlano M;Numico G;Comino A;Attard M;Reelfs O;Gusterson B;Bell AK;Heath V;Tavassoli M;Farrell PJ;Smith P;Lu X;Crook T;,2003,Cancer Cell,3,387,402,12726864,,fixed/frozen,DNA,none,cloned,true,true,true,true,true,true,true,true,true,true,false
171,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Denmark,Northern Europe,Europe,More developed regions,Aarhus University Hospital,1986-2005,,"RX (5-6 fx/week for 6,5 or 5,5 weeks)",,,180,125,survival/response,not related to,"Overall, mutations in TP53 were not associated with the endpoints. However, when dichotomising according to TP53 status and evaluating the effect of the overall treatment time then tumours with mutant TP53 did benefit from 6 instead of 5fx/wk regarding local control, P=0.005; RR: 0.33 (C.I 95%:0.15-0.75) whereas WT-tumours did not (P=0.9). These observations were also reflected in the disease-specific and crude survival. Thus, if all patients were considered regardless of treatment schedule, then TP53-mutations were not related to local control or survival. However, mutations in TP53 may be associated with HNSCC that benefit of a reduced overall treatment time of radiotherapy.",2232,,The possible role of TP53 mutation status in the treatment of squamous cell carcinomas of the head and neck (HNSCC) with radiotherapy with different overall treatment times,Eriksen JG;Alsner J;Steiniche T;Overgaard J;,2005,Radiother Oncol,76,135,142,16024113,,fixed,DNA,DHPLC,direct,false,false,true,true,true,true,true,true,true,false,false
207,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,"Department of otolaryngology, Okayama University Hospital",1994-2005,,,64.0,40-81,71,28,survival,not related to,p53 mutation status alone did not give significant survival changes either for DFS or OS.,2411,2191,Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer,Gunduz M;Beder LB;Gunduz E;Nagatsuka H;Fukushima K;Pehlivan D;Cetin E;Yamanaka N;Nishizaki K;Shimizu K;Nagai N;,2007,Cancer Sci,99,531,538,18081876,,frozen,DNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
209,"HEAD&NECK, NOS","HEAD&NECK, NOS","Squamous cell carcinoma, NOS",USA,Northern America,Americas,More developed regions,Multicenter (ECOG/RTOG studies),1996-2002,,SU +/- (RX or CX+RX),75.0,0-128,420,224,survival,associated with bad,"As compared with wild-type TP53, the presence of any TP53 mutation was associated with decreased overall survival (hazard ratio for death, 1.4; 95% confidence interval [CI], 1.1 to 1.8; P = 0.009), with an even stronger association with disruptive mutations (hazard ratio, 1.7; 95% CI, 1.3 to 2.4; P<0.001) and no significant association with nondisruptive mutations (hazard ratio, 1.2; 95% CI, 0.9 to 1.7; P= 0.16). In multivariate analyses a disruptive TP53 alteration, as compared with the absence of a TP53 mutation, had an independent, significant association with decreased survival (hazard ratio, 1.7; 95% CI, 1.2 to 2.4; P = 0.003).",2471,,TP53 mutations and survival in squamous-cell carcinoma of the head and neck,Poeta ML;Manola J;Goldwasser MA;Forastiere A;Benoit N;Califano JA;Ridge JA;Goodwin J;Kenady D;Saunders J;Westra W;Sidransky D;Koch WM;,2007,N Engl J Med,357,2552,2561,18094376,,fixed,DNA,AmpliChip/DHPLC/none,direct,true,true,true,true,true,true,true,true,true,false,false
48,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,"Leukemia, NOS",Denmark,Northern Europe,Europe,More developed regions,"The Juliane Marie Center, Rigshospitalet, Copenhagen",,therapy related leukemia,,,0-54,77,21,survival,associated with bad,"Mutations of p53 were more common in older patients (P =.036) and were associated with an extremely poor prognosis (P =.014), apparently restricted to the 15 cases with LOH of p53 ( P =.046).",1521,,"Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis",Christiansen DH;Andersen MK;Pedersen-Bjergaard J;,2001,J Clin Oncol,19,1405,1413,11230485,,frozen,DNA/RNA,SSCP,direct,true,true,true,true,true,true,true,true,true,false,false
67,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,"Myelodysplastic syndrome, NOS",Japan,Eastern Asia,Asia,More developed regions,Kyoto Prefectural University of Medecine,,,,18.0,0.6-148,118,16,survival,associated with bad,"We applied the International Prognostic Scoring System (IPSS) to our series of 118 patients with myelodysplastic syndrome (MDS) to determine its validity, and also used univariate and multivariate analyses to evaluate the prognostic significance of TP53 configurations. Sixteen patients with the mutation had a strikingly worse prognosis and the multivariate analysis demonstrated that this alteration was the most significant factor.",1674,,International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome,Kita-Sasai Y;Horiike S;Misawa S;Kaneko H;Kobayashi M;Nakao M;Nakagawa H;Fujii H;Taniwaki M;,2001,Br J Haematol,115,309,312,11703325,,,,SSCP,direct,false,false,true,true,true,true,true,false,false,false,false
75,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,"Acute myeloid leukemia, NOS",Japan,Eastern Asia,Asia,More developed regions,Hospital of Nippon Medical School,1986-2000,,CX (BHAC-DMP regimen),21.0,0.1-118,170,20,survival/response,associated with bad,...the mutant p53 group had a significantly shorter survival time (P<0.0001; Fig.3B) and a significantly shorter complete remission than the wild-type p53 group (P<0.0001; Fig.4B).,1713,,Loss of DCC Gene Expression Is of Prognostic Importance in Acute Myelogenous Leukemia,Inokuchi K;Yamaguchi H;Hanawa H;Tanosaki S;Nakamura K;Tarusawa M;Miyake K;Shimada T;Dan K;,2002,Clin Cancer Res,8,1882,1888,12060632,,,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
98,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,"Acute myeloid leukemia, NOS",Czech Republic,Eastern Europe,Europe,More developed regions,University Hospital Brno,2000-2002,non-selected,,7.0,1-67,64,12,survival/response,associated with bad,i) the presence of p53 mutations was detected in 13 of 62 tested AML cases (21%) and in 1 of 4 tested myelodysplastic syndrome (MDS) cases by FASAY; ii) the presence of p53 mutation was shown to be a poor prognostic/predictive factor in AML (p=0.03/0.002);,1827,,High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast,Pavlova S;Mayer J;Koukalova H;Smardova J;,2003,Int J Oncol,23,121,131,12792784,,fresh,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
132,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,"Precursor cell lymphoblastic leukemia, NOS",Italy,Southern Europe,Europe,More developed regions,Oncology Pediatric Service of II University of Naples,1992-2000,children (median age: 4 years),AIEOP ALL '91 and '95 protocols (prednisone in prephase induction therapy).,,0-160,62,9,survival/response,associated with bad,"EFS and OS were inversely correlated to mutated p53 or overexpression of p53 (p=0.0039; p=0.035 respectively) in univariate but not in multivariate (age, gender, WBC, immunophenotype, prednisone response) model. p53 alterations were uncommon and alone not strong independent predictors of outcome, but they were correlated to poor response to therapy with PDN and inversely correlated to EFS and OS in univariate analysis.",2096,,Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL),Addeo R;Caraglia M;Baldi A;D'Angelo V;Casale F;Crisci S;Abbruzzese A;Vincenze B;Campioni M;Di Tullio MT;Indolfi P;,2005,Cancer Biol Ther,4,32,38,15684603,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
166,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma,UK,Northern Europe,Europe,More developed regions,Birmingham,2001-2003,attendance to the outpatient clinic,,71.0,25-217,155,6,survival,associated with bad,"Patients  with an ATM mutation had a statistically significant reduction in both Overall Survival and Treatment-Free Survival (log rank test, p<0,001, p=0,007, respectively) compared with patients whose tumors retained wt ATM and TP53 genes. Patients whose tumors carried TP53 mutations had the shortest OS. The survival differences among all 3 genetic subgroups were highly statistically significant (p<0,001 for OS and TSF).",2209,,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL,Austen B;Powell JE;Alvi A;Edwards I;Hooper L;Starczynski J;Taylor AM;Fegan C;Moss P;Stankovic T;,2005,Blood,106,3175,3182,16014569,,frozen,DNA,DHPLC,direct,false,true,true,true,true,true,true,true,true,false,false
190,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,Adult T-cell leukemia/lymphoma (HTLV-1 positive),NA,NA,NA,NA,"Necker Hospital, Paris, France & National Insitutes of Health, Bethesda, MD",,,AZT,,,14,6,response,associated with bad,"Our results demonstrate that all ATL patients carrying a wild-type p53 gene responded to AZT treatment and went into partial or complete remission. In contrast, all patients carrying a mutated p53 at diagnosis did not respond to AZT treatment and died within a short period of time. Thus, a total correlation between p53 and AZT response was found and makes the results highly significant.",2343,,Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence,Datta A;Bellon M;Sinha-Datta U;Bazarbachi A;Lepelletier Y;Canioni D;Waldmann TA;Hermine O;Nicot C;,2006,Blood,108,1021,1029,16569765,,fresh,RNA,none,cloned,false,false,true,true,true,true,true,true,false,false,false
208,HEMATOPOIETIC AND RETICULOENDOTHELIAL SYSTEMS,HEMATOP. SYSTEM,Multiple myeloma (C42.1),USA,Northern America,Americas,More developed regions,Eastern Cooperative Oncology Group,,clinical trial E9486/E9487,,5.0,,268,9,survival,associated with bad,The presence of TP53 mutations was associated with very poor survival of only one and a half year.,2424,,Clinical significance of TP53 mutation in myeloma,Chng WJ;Price-Troska T;Gonzalez-Paz N;Van WS;Jacobus S;Blood E;Henderson K;Oken M;Van NB;Greipp P;Rajkumar SV;Fonseca R;,2007,Leukemia,21,582,584,17215851,,,DNA,CDGE,direct,true,true,true,true,true,true,true,true,true,true,false
120,LARYNX,LARYNX,"Squamous cell carcinoma, NOS",Italy,Southern Europe,Europe,More developed regions,"Clinica Otorinolaringoiatrica I, Milano",1993-1997,primary cancer,SU,36.0,4-92,84,24,survival,not related to,"No statistical difference in overall survival was found between the patients with wild-type and mutated p53 gene (62.5% vs 63.3%, p=.94).",2003,459,Association between p53 gene mutations and tobacco and alcohol exposure in laryngeal squamous cell carcinoma,Ronchetti D;Neglia CB;Cesana BM;Carboni N;Neri A;Pruneri G;Pignataro L;,2004,Arch Otolaryngol Head Neck Surg,130,303,306,15023836,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
49,LIVER AND INTRAHEPATIC BILE DUCTS,LIVER,"Hepatocellular carcinoma, NOS (C22.0)",Chinese Taipei (Taiwan),South Eastern Asia,Asia,Less developed regions,National Tawain University Hospital,1983-1992,unifocal HCC; FU>1 year,SU,,0-70,138,51,survival,associated with bad,"HCC patients with mutated p53 gene had a worse outcome (5-year survival 18% vs 38%, p<0.008). p53 gene mutation is common in advanced HCC, occurs as a late event in HCC growth, correlates with tumor progression and aggression.",351,351,Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC,Hsu HC;Peng SY;Lai PL;Chu JS;Lee PH;,1994,Int J Oncol,4,1341,1347,21567059,"See ref 2021, 2341",frozen,DNA,SSCP,direct,true,true,true,true,true,true,true,true,true,true,false
188,LIVER AND INTRAHEPATIC BILE DUCTS,LIVER,"Hepatocellular carcinoma, NOS (C22.0)",Chinese Taipei (Taiwan),South Eastern Asia,Asia,Less developed regions,National Taiwan University Hospital,1984-1997,"Primary cancer, no chemotherapy before surgery",,,,156,72,survival,associated with bad,"Mutation of p53 was associated with lower 5-year survival rate, p<0,0004.",2341,351,"Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma",Yuan RH;Jeng YM;Chen HL;Lai PL;Pan HW;Hsieh FJ;Lin CY;Lee PH;Hsu HC;,2006,J Pathol,209,549,558,16739096,See also ref 2021,frozen,DNA,SSCP,direct,true,true,true,true,true,true,true,true,true,true,false
220,LIVER AND INTRAHEPATIC BILE DUCTS,LIVER,"Hepatocellular carcinoma, NOS (C22.0)",China,Eastern Asia,Asia,Less developed regions,Sun Yat-sen University,,,,,,54,14,recurrence,associated with bad,p53 mutation was significantly associated with shorter recurrence-free survival (P = 0.004).,2495,,Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China,Su H;Zhao J;Xiong Y;Xu T;Zhou F;Yuan Y;Zhang Y;Zhuang SM;,2008,Mutat Res,641,27,35,18358501,,frozen,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
22,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),The Netherlands,Western Europe,Europe,More developed regions,"The Netherlands Cancer Institute, Amsterdam",,consecutive primary cancers,SU,,0-70,54,37,survival,not related to,"Patients with p53 alterations in their tumors tended to have a better prognosis than those without a p53 alteration; however, this difference was lost when cases with a K-ras mutation were omitted from the analysis.",511,,Comparative analysis of p53 gene mutations and protein accumulation in human non-small-cell lung cancer,Top B;Mooi WJ;Klaver SG;Boerrigter L;Wisman P;Elbers HR;Visser S;Rodenhuis S;,1995,Int J Cancer,64,83,91,0007615358,,frozen,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
21,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Japan,Eastern Asia,Asia,More developed regions,Kitano Hospital; The Center for adlut disease (Osaka),1991-1995,consecutive primary cancers; excluding stage 4,"SU, RX, CX (Vindesine, CISP)",31.9,0-60,204,75,survival,associated with bad,"The overall survival rate of patients with mutant p53 adenocarcinomas was strikingly worse than that of patients whose tumors had wild-type p53 (35.7% vs 53.8%; P=0.041), but no significant difference in survival was found in the patients with NSCLC and squamous cell carcinoma. The overall survival rate of patients with mutations in exon 7 was worse than that of patients with wild-type p53 in NSCLCs and adenocarcinomas (42.9% vs 56.0%; P=0.025 and 33.3% vs 53.8%; P=0.048, respectively), whereas the overall survival of patients with mutations in exon 5 was almost the same as that of patients with wild-type p53. In addition, the overall survival rate of patients with mutations in exon 8 was strikingly worse than that of patients with wild-type p53 in NSCLCs, adenocarcinomas and squamous cell carcinomas (22.9% vs 56.0%; P<0.001, 19.0% vs 53.8%; P=0.004 and 33.3% vs 62.5%; P=0.042, respectively). Multivariate analysis with the Cox regression model of patients with NSCLC, adenocarcinoma and squamous cell carcinoma indicated that mutations in exon 8 were best correlated with the overall survival rate, followed by lymph node status (P<0.001, P=0.015 and P=0.006, respectively), and mutations in exon 7 of NSCLC were also revealed to have good correlation, followed by lymph node status and mutations in exon 8 (P=0.031). Mutation of p53 was a poor prognostic factor for adenocarcinoma as described previously. Moreover, mutations in exon 8 were more useful indicators of prognosis not only for adenocarcinoma but also for NSCLC. Worse overall survival of the patients with mutations in exon 8 of p53 was suggested to be associated with codon 273 mutations as well as mutations between codon 280 and 285 included into the H2 alpha helix corresponding to residues 278-286.",823,823,Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer,Huang C;Taki T;Adachi M;Konishi T;Higashiyama M;Miyake M;,1998,Oncogene,16,2469,2477,0009627113,See ref 1334,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
47,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),"Europe, NOS","Europe, NOS",Europe,More developed regions,,1986-1992,consecutive primary cancers,,,0-83,151,34,survival,associated with bad,"The Spanish NSCLC patients contained missense mutations (9/59, 15%) and a relatively high percentage of null mutations (5/59, 8%) while the Polish patients mostly harbored missense mutations (9/92, 10%) and only one tumor contained a null type (1/92, 1%). Moreover, most TP53 missense mutations in the Spanish group were located outside the conserved regions, whereas the same mutations in the Polish group affected conserved amino acids. Furthermore, the Polish patients harbored a high percentage of G-->A transitions (most of them at non-CpG sites), while G-->T transversions were predominant in the Spanish group. The presence of missense mutations did not confer a worse clinical outcome in these subsets of NSCLC patients. However, patients whose tumors contained null TP53 gene mutations had a 5 month median disease-free survival time in contrast with 42 months in those patients without mutations (P=0.008).",942,,TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis,de Anta JM;Jassem E;Rosell R;Martinez-Roca M;Jassem J;Martinez-Lopez E;Monzo M;Sanchez-Hernandez JJ;Moreno I;Sanchez-Cespedes M;,1997,Oncogene,15,2951,2958,0009416838,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
24,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Japan,Eastern Asia,Asia,More developed regions,"National Cancer Hospital, Tokyo",1985-1994,consecutive primary cancers; stage 1,SU,51.8,5-151,103,49,survival,associated with bad,p53 missense mutations rather than null mutations were associated with poor prognosis (P < 0.001 in missense mutations and P=0.243 in null mutations).,1204,,Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma,Tomizawa Y;Kohno T;Fujita T;Kiyama M;Saito R;Noguchi M;Matsuno Y;Hirohashi S;Yamaguchi N;Nakajima T;Yokota J;,1999,Oncogene,18,1007,1014,0010023676,,frozen,DNA,SSCP,direct,true,true,true,true,true,true,true,true,true,true,false
210,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Austria,Western Europe,Europe,More developed regions,University of Vienna,1995-1997,"stage IIIA,B","SU, CX (CISP)",27.0,,24,8,survival/response,associated with bad,"A normal TP53 genotype proved to be significantly associated with major response to chemotherapy (P <.001). Overall, no association was found between p53 protein expression and TP53 genotype. A normal TP53 genotype was found to be highly sensitive in predicting response to treatment, whereas a mutant genotype was revealed to be specific in predicting lack of response. The difference in overall length of survival was significant between patients exhibiting a normal TP53 genotype (corresponding to those whose disease responded to chemotherapy) and patients showing mutant TP53 genotype (corresponding to those who had disease resistant to chemotherapy, P =.027).",1255,,The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer,Kandioler-Eckersberger D;Kappel S;Mittlbock M;Dekan G;Ludwig C;Janschek E;Pirker R;Wolner E;Eckersberger F;,1999,J Thorac Cardiovasc Surg,117,744,750,0010096970,,frozen,DNA,,direct,true,true,true,true,true,true,true,true,true,true,false
23,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Japan,Eastern Asia,Asia,More developed regions,"Cancer Institute Hospital, Tokyo",1989-1993,consecutive primary cancers,"SU, CX",61.0,2-84,144,65,survival,associated with bad,"Presence of p53 mutations was an independent prognostic factor with a statistical trend (P = 0.14) in stage I patients but not in all cases. When examined by mutational pattern, null mutation was a significant indicator of poor outcome by multivariate analysis (P = 0.03) in stage I patients, whereas cases with missense mutations and without mutations did not differ (P = 0.76).",1314,1218,p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas,Hashimoto T;Tokuchi Y;Hayashi M;Kobayashi Y;Nishida K;Hayashi S;Ishikawa Y;Tsuchiya S;Nakagawa K;Hayashi J;Tsuchiya E;,1999,Cancer Res,59,5572,5577,0010554037,Some mutations reported in ref 1218; Add info in ref 1481; see also ref 2335,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,false,false,false,false
52,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),NA,NA,NA,NA,,,,,,,68,27,survival,not related to,"The relationship between the factors examined in the present study, clinicopathological features, and survival of the patients did not reveal any significant correlations.",1375,1375,Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression,Gorgoulis VG;Zacharatos P;Kotsinas A;Liloglou T;Kyroudi A;Veslemes M;Rassidakis A;Halazonetis TD;Field JK;Kittas C;,1998,Am J Pathol,153,1749,1765,9846966,Add info from ref 1376 and 1557;,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,false,false,false
38,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Poland,Eastern Europe,Europe,More developed regions,Bialystok Medical School,,consecutive primary cancers,SU,,12.1-40.7,74,34,survival,associated with bad,"In the univariate analysis (log rank test), positive results in the p53-M test and the p53-PE test were significantly associated with overall survival (P < 0.001 and P = 0.005, respectively). In the multivariate analysis (Cox's proportional hazard model), a positive result for the p53-M test significantly increased relative risk for overall survival (RR 9.56; 95% CI 2.62-34.87; P < 0.001). Results confirmed with a larger serie published in Laudanski et al., Eur Respir J 2001 (PMID: 11401061)",1419,,p53 gene mutation and protein expression in operable non-small cell lung cancer in Poland,Niklinska W;Burzykowski T;Chyczewski L;Rusin MR;Furman M;Laudanski J;Chyczewska E;Sulik M;Niklinski J;,2000,Eur J Cancer Prev,9,81,87,10830574,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
66,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Japan,Eastern Asia,Asia,More developed regions,"Kyushu University Hospital, Fukuoka",1995-1998,consecutive primary cancers,,,0-72,145,51,survival,associated with bad,"Multivariate analysis revealed that the histological subtype including BAC-invasive was a strong, independent, and significant prognostic factor (P < 0.03), as were tumor size and pathological stage (P < 0.001 and 0.002, respectively) for overall survival. However, the occurrence of p53 mutation itself was seen to be significant only in case of the univariate analysis. Therefore, histological subtyping may be a better prognostic indicator than is p53 mutation.",1615,1571,Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma,Koga T;Hashimoto S;Sugio K;Yoshino I;Mojtahedzadeh S;Matsuo Y;Yonemitsu Y;Sugimachi K;Sueishi K;,2001,Clin Cancer Res,7,1730,1738,11410513,,fixed,DNA,SSCP,direct,true,true,true,true,true,true,true,true,false,false,false
20,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Norway,Northern Europe,Europe,More developed regions,Norwegian National Hospital; Haukeland Hospital (Oslo),1988-1996,consecutive primary cancers; prospective study,SU,35.0,0-144,148,83,survival,associated with bad,"Patients with mutations in p53 had a significantly higher risk for lung cancer-related death and for death from all causes than those with wild-type p53 [hazard ratio (HR) = 2.09 and 95% confidence interval (CI) = 1.20-3.64 and HR = 1.69 and 95% CI = 1.06-2.70, respectively]. Mutations in p53 related to even still poorer lung cancer-related prognosis were found at the following locations: (a) exon 8 (HR = 3.5; 95% CI, 1.59-7.71)]; (b) the structural domains L2 + L3 (HR = 2.36; 95% CI, 1.18-4.74), and (c) codons involved in zinc binding (HR = 11.7; 95% CI, 3.56-38.69). Together, the biologically functional group of severe flexible mutants (codons 172, 173, 175, 176, 179, 181, 238, 245, and 267) and severe contact mutants (248, 282) were significantly related to shorter lung cancer-related survival (HR = 4.16; 95% CI, 1.93-8.97).",1646,338,p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients,Skaug V;Ryberg D;Kure EH;Arab MO;Stangeland L;Myking AO;Haugen A;,2000,Clin Cancer Res,6,1031,1037,10741731,,frozen,DNA,SSCP,direct,false,false,true,true,true,true,true,true,false,false,false
25,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),NA,NA,NA,NA,"Cologne, Munich (Germany); Houston (USA)",,retrospective study,"SU, RX",86.8,63.5-105.2,103,46,survival,not related to,Survival rate did not differ between NSCL with and without p53 mutation and subgroup analysis demonstrated a tendancy towards a reduced probability in SCC which was not statistically significant.,1647,,"Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer",Schneider PM;Praeuer HW;Stoeltzing O;Boehm J;Manning J;Metzger R;Fink U;Wegerer S;Hoelscher AH;Roth JA;,2000,Br J Cancer,83,473,479,10945494,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
63,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Chinese Taipei (Taiwan),South Eastern Asia,Asia,Less developed regions,Veterans General Hospital-Taichung,1993-1998,consecutive primary cancers,,,,81,13,survival,not related to,"The p53 direct sequencing data indicated that 13 of 81 patients (16.0%) had p53 mutations. However, Kaplan-Meier analysis showed that p53 protein and MDM2 protein expression and p53 mutation were not useful as prognostic factors.",1659,1072,MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer,Ko JL;Cheng YW;Chang SL;Su JM;Chen CY;Lee H;,2000,Int J Cancer,89,265,270,10861503,,frozen,RNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
87,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),USA,Northern America,Americas,More developed regions,"Johns Hopkins Hospital, Johns Hopkins Bayview Medical Center, Froedtert Memorial Lutheran Hospital",1995-1999,"stage I, prospective study",?,27.0,1-71,188,104,survival,associated with bad,"p53 mutations were detected in 55% (104/188) of tumors. These mutations were associated with non-bronchoalveolar tumors, a history of alcohol consumption, and younger patient age. The risk of death was statistically significantly higher in patients with p53 mutations in their tumors (hazard ratio [HR] = 1.6, 95% confidence interval [CI] = 1.0 to 2.4; P =.049) than in patients with wild-type p53 in their tumors. Tumor stage, the presence of a p53 mutation, and increasing patient age were statistically significant predictors of patient death in the entire patient group; however, the statistically significant prognostic effect of p53 mutation was limited to patients with stage I NSCLC (stage I HR = 2.8, 95% CI = 1.4 to 5.6; stage II HR = 1.8, 95% CI = 0.74 to 4.4; and stage III HR = 0.70, 95% CI = 0.32 to 1.5).",1814,1211,p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study,Ahrendt SA;Hu Y;Buta M;McDermott MP;Benoit N;Yang SC;Wu L;Sidransky D;,2003,J Natl Cancer Inst,95,961,970,12837832,"See refs 1211,1259,1633. Data provided by S Ahrendt",frozen,DNA,none/AmpliChip,direct,true,true,true,true,true,true,true,true,true,true,false
149,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),USA,Northern America,Americas,More developed regions,"Mayo Clinic, Rochester",1991-1992,primary cancer,SU,,0-72,91,42,survival,not related to,"Neither p53 mutation nor abnormal p53 immunohistochemical expression is significantly associated with poorer survival (p=0,8 and 0,5, respectively). However, the presence of p53 overexpression or a p53 mutation in association with cyclin D1 overexpression displayed a significant relationship with survival (p=0,004 and 0,003, respectively)",2150,464,Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma,Burke L;Flieder DB;Guinee DG;Brambilla E;Freedman AN;Bennett WP;Jones RT;Borkowski A;Caporaso NA;Fleming M;Trastek V;Pairolero P;Tazelaar H;Midthun D;Jett JR;Liotta LA;Travis WD;Harris CC;,2005,Clin Cancer Res,11,232,241,15671551,,frozen,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
186,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),Poland,Eastern Europe,Europe,More developed regions,"Thoracic Surgery Department, Medical University of Gdansk",1996-2004,,"SU, pre-op treatment",,,240,62,survival,not related to,"There was no correlation between survival curves according to the presence of TP53 somatic mutations (log-rank, p=0,48). In the univariate Cox proportional model, the presence of somatic TP53 mutations was not associated with worse survival (HR=0,96, 95% CI: 0,69-1,34, p=0,83). This result remained unchanged when corrected for age, sex, histology, pT and pN category (HR=1,91, 95% CI: 0,65-1,28, p=0,60).",2336,1940,Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism,Szymanowska A;Jassem E;Dziadziuszko R;Borg A;Limon J;Kobierska-Gulida G;Rzyman W;Jassem J;,2006,Lung Cancer,52,9,14,16499995,,fixed,DNA,SSCP/None,direct,false,false,false,true,true,true,true,false,false,false,false
225,BRONCHUS AND LUNG,LUNG,Non-small cell carcinoma (C34._),"Northern America, NOS",Northern America,Americas,More developed regions,Multiple; JRB10 trial,,completely resected T2N0 and T1-2N1 tumors,vinorelbine/cisplatin,,0-120,397,124,survival,not related to,Mutations in p53 gene were neither prognostic for survival nor predictive of a differential benefit from adjuvant chemotherapy.,2383,,Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer,Tsao MS;viel-Ronen S;Ding K;Lau D;Liu N;Sakurada A;Whitehead M;Zhu CQ;Livingston R;Johnson DH;Rigas J;Seymour L;Winton T;Shepherd FA;,2007,J Clin Oncol,25,5240,5247,18024870,,fixed/frozen,DNA,DHPLC,direct,false,false,false,true,true,true,true,true,false,false,false
57,LYMPH NODES,LYMPH NODES,B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma,Spain,Southern Europe,Europe,More developed regions,"Virgen de la Salud Hospital, Toledo",,,,,0-100,62,11,survival,associated with bad,"Cases characterized by p27 anomalous expression display concurrent inactivation of p21 (provided by p53 mutations) and/or p16 CKIs in 11 of 14 LBCL cases (P = 0.040). When the relationship between the association of inactivated CKIs and overall survival was considered, a significant relationship was found between a lower overall survival probability and an increased number of inactivated CKIs in LBCL cases, with the worst prognosis for the cases displaying concurrent p53, p16, and p27 alterations. In this same series of data, Burkitt's lymphoma patients seem to behave in a different way than LBCLs, with p53 and p16 alteration being mutually exclusive and the association with p27 anomalous expression not being clinically significant.",1573,305,"Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27",Sanchez-Beato M;Saez AI;Navas IC;Algara P;Sol MM;Villuendas R;Camacho F;Sanchez-Aguilera A;Sanchez E;Piris MA;,2001,Am J Pathol,159,205,213,11438467,See also ref 895,,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
80,LYMPH NODES,LYMPH NODES,"Malignant lymphoma, large B-cell, diffuse, NOS",France,Western Europe,Europe,More developed regions,Multicenter study,1987-1997,de novo DLBCL with low or low-intermediate risk (IPI),CX (ACVBP or NCVBP),80.0,16-141,69,16,survival,associated with bad,"The presence of a p53 gene mutation affected survival (P = 0.01), with a 6-year survival rate estimated to be 44% in mutated patients, compared with 79% in non-mutated ones. Using a stepwise Cox model, p53 mutation constituted the only parameter affecting survival (relative risk = 2.7, P = 0.03). A p53(+)/p21(-) immunohistochemical pattern (n = 15), suggestive of a disrupted p53 function, strongly correlated with p53 gene status and was associated with a lower 6-year survival rate when compared with a p53(-) or p53(+)/p21(+) phenotype (47% versus 74%, P = 0.05).",1740,,p53 gene mutations are associated with poor survival in low and low- intermediate risk diffuse large B-cell lymphomas,Leroy K;Haioun C;Lepage E;Le Metayer N;Berger F;Labouyrie E;Meignin V;Petit B;Bastard C;Salles G;Gisselbrecht C;Reyes F;Gaulard P;,2002,Ann Oncol,13,1108,1115,12176791,,frozen,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
82,LYMPH NODES,LYMPH NODES,"Follicular lymphoma, NOS",Spain,Southern Europe,Europe,More developed regions,"Hospital de la Santa Creu I Sant Pau, Barcelona",,lymphoma proceeding from germinal center with t(14;18)(q21;q32),,19.5,,43,7,survival,associated with bad,"We did not find significant differences in survival between patients with FL who showed exclusively bcl-6 mutations and those without bcl-6 mutations, but those patients with a high International Progostic Index score and p53 mutations showed the lowest overall survival (p = 0.002)",1749,,Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement,Bellido M;Capello D;Altes A;Estivill C;Gaidano G;Pujol R;Bordes R;Baiget M;Saglio G;Sierra J;Nomdedeu JF;,2002,Haematologica,87,908,917,12217802,,fresh,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
95,LYMPH NODES,LYMPH NODES,B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma,UK,Northern Europe,Europe,More developed regions,Various Hospitals in UK,,,,31.5,,138,23,survival,associated with bad,"p53 mutations resulted not only in a shorter survival but, notably also in selective resistance to alkylating agents, fludarabine and gamma-irradiation. In contrast, no such effect was observed for vincristine, anthracyclines and glucocorticoids.",1824,,Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy,Sturm I;Bosanquet AG;Hermann S;Guner D;Dorken B;Daniel PT;,2003,Cell Death Differ,10,477,484,12719725,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
156,LYMPH NODES,LYMPH NODES,"Malignant lymphoma, large B-cell, diffuse, NOS",UK,Northern Europe,Europe,More developed regions,"St Bartholomew's hospital, London",,avaibility of FL & DLBCL samples,,80.0,24-229,29,8,survival,not related to,"Overall survival from diagnosis or documented histological transformation was not significantly different between those patients with a TP53 mutation and those with wtTP53 (p=0,19 and p=0,45, respectively).",2176,2176,A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma,Davies AJ;Lee AM;Taylor C;Clear AJ;Goff LK;Iqbal S;Cuthbert-Heavens D;Calaminici M;Norton AJ;Lister TA;Fitzgibbon J;,2005,Leukemia,19,1459,1465,15902285,,frozen,DNA,SSCP,direct,true,true,true,true,true,true,true,true,true,true,false
181,LYMPH NODES,LYMPH NODES,Mantle cell lymphoma,NA,NA,NA,NA,Lymphoma Leukemia Molecular Profiling Project,,Patients Cyclin D1-positive,,,1-168,82,16,survival,associated with bad,"There was a significant difference (P=0,0033) in the median OS of patients with p53 point mutations (1,1 years) compared with those with only wild-type p53 alleles (3,1 years).",2273,,Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphomas,Greiner TC;Dasgupta C;Ho VV;Weisenburger DD;Smith LM;Lynch JC;Vose JM;Fu K;Armitage JO;Braziel RM;Campo E;Delabie J;Gascoyne RD;Jaffe ES;Muller-Hermelink HK;Ott G;Rosenwald A;Staudt LM;Im MY;Karaman MW;Pike BL;Chan WC;Hacia JG;,2006,Proc Natl Acad Sci U S A,103,2352,2357,16461462,,,DNA,DHPLC,direct,false,false,false,true,true,true,true,false,false,false,false
183,LYMPH NODES,LYMPH NODES,"Malignant lymphoma, large B-cell, diffuse, NOS",Japan,Eastern Asia,Asia,More developed regions,Nagoya University Hospital,1987-2006,Negative for HIV,CX (CP/anthracycline),34.0,,96,19,survival/response,associated with bad,"Complete remission (CR) rates differed significantly between the patients with p53 mutations and those without such mutations. Eight (42,1%) of the 19 patients with p53 mutations underwent CR, compared with 60 (77,9%) of the 77 patients with wt p53 gene (P = 0,0040). There was a significant difference in overall survival between the 2 groups. For the patients without p53 mutations, the Kaplan-Meier estimate of the survival rate at 5 years was 58,8%, whereas the rate waas 30% for the patients with p53 mutations (P = 0,027).",2285,778,Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma,Hiraga J;Kinoshita T;Ohno T;Mori N;Ohashi H;Fukami S;Noda A;Ichikawa A;Naoe T;,2006,Int J Hematol,84,248,255,17050200,Prevalence impossible to establish bcse link with 778 not clear,fresh,DNA,DHPLC,direct,false,false,false,true,true,true,true,true,false,false,false
226,OTHER AND UNSPECIFIED PARTS OF MOUTH,MOUTH (other),"Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,"Hokkaido University Dental Hospital, Sapporo",1996-2006,untreated oral SCC who underwent curative surgery,SU,30.5,,60,42,recurrence,associated with bad,"The patients with dominant negative mutation had significantly shorter disease-free survival than patients with no mutation (log-rank test, p<0.001) and those with a recessive mutation (p<0.016). There were slight significant differences in disease-free survival were found between the patients with tumours harbouring a recessive p53 mutation and those with tumours harbouring a wild-type p53 (p<0.038). The presence and absence of a dominant negative p53 mutation may thus provide a predictor of early recurrence in oral SCC patients.",2585,,Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer,Hassan NM;Tada M;Hamada J;Kashiwazaki H;Kameyama T;Akhter R;Yamazaki Y;Yano M;Inoue N;Moriuchi T;,2008,Cancer Lett,270,108,119,18555592,,frozen,RNA,FASAY,cloned,false,false,true,true,true,true,true,true,false,false,false
227,NASOPHARYNX,NASOPHARYNX,"Carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Various institutions in Kyushu,1985-2006,,,30.0,,51,8,survival,not related to,p53 mutation status was not related to survival.,2593,,Overexpression of inducible nitric oxide synthase and accumulation of 8-OHdG in nasopharyngeal carcinoma,Segawa Y;Oda Y;Yamamoto H;Uryu H;Shiratsuchi H;Hirakawa N;Tomita K;Yamamoto T;Oda S;Yamada T;Komune S;Tsuneyoshi M;,2008,Histopathology,52,213,223,18184270,,fixed/frozen,DNA,none,direct,false,false,false,false,false,false,false,false,false,false,false
184,OROPHARYNX,OROPHARYNX,"Squamous cell carcinoma, NOS",Italy,Southern Europe,Europe,More developed regions,National Cancer Institute of Milan,1990-1999,,SU +/- RX,70.0,12-129,90,35,recurrence/survival,not related to,"Statistical analysis showed that HPV-positive status significantly affects all investigated end points: overall survival (P=0,0018), incidence of tumor relapse (P=0,0371), and second tumor (P=0,0152), whereas TP53 and p16INK4& status and p16 expression were not prognostic by themselves. Thus, a more favorable outcome was generally observed in the HPV-positive subset. In contrast, for HPV-negative patients, overlapping outcomes were observed in mutated TP53 and wt TP53 subsets. Moreover, the presence of HPV in the primary tumor apparently removed the risk of developping an second tumor (ST), and wt TP53 status seemed to be associated with a lower incidence of ST, as compared with mutated TP53 status, although this did not reach statistical significance (P=0,1182).",2305,2305,High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma,Licitra L;Perrone F;Bossi P;Suardi S;Mariani L;Artusi R;Oggionni M;Rossini C;Cantu G;Squadrelli M;Quattrone P;Locati LD;Bergamini C;Olmi P;Pierotti MA;Pilotti S;,2006,J Clin Oncol,24,5630,5636,17179101,See also ref 2330,fixed,DNA,dg-DGGE,direct,false,false,true,true,true,true,true,true,true,false,false
84,OVARY,OVARY,"Carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Gifu University Hospital,1984-1991,serous cystadenocarcinoma and endometrioid adenocarcinoma,"SU, CX (CISP+doxo+CP)",,,31,13,survival,not related to,"The presence of p53 gene mutation did not correlate with histological grade, response to primary therapy and survival. These findings suggest that mutational alterations of the p53 gene are involved in the development of a significant proportion of some ovarian carcinomas (SCAs or EAs), especially in advanced stages. However, they may not be a marker predicting the biological behaviour or the outcome of the disease",431,,Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance,Niwa K;Itoh M;Murase T;Morishita S;Itoh N;Mori H;Tamaya T;,1994,Br J Cancer,70,1191,1197,0007981076,,fixed,DNA,SSCP,direct,false,false,true,true,true,true,true,false,false,false,false
34,OVARY,OVARY,"Cancer, NOS",Norway,Northern Europe,Europe,More developed regions,"Norwegian Radium Hospital, Oslo",,advanced epithelial ovarian cancers,"SU, CX (paclitaxel/CISP; CP/CISP)",,,45,29,response,not related to,"When relapse-free survival was estimated for all patients with TP53 alterations in their tumours, a significant better outcome for the paclitaxel/cisplatin group was found compared with the patient group receiving cyclophosphamide and cisplatin therapy (P = 0.002). We did not observe an association between TP53 tumour status and prognosis for patients who received paclitaxel/cisplatin combination treatment, indicating that the effect of this therapy is not influenced by this parameter.",1014,,Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status,Smith-Sorensen B;Kaern J;Holm R;Dorum A;Trope C;Borresen-Dale AL;,1998,Br J Cancer,78,375,381,0009703286,,frozen,DNA,TTGE,direct,true,false,false,true,true,true,true,true,false,true,false
39,OVARY,OVARY,"Cancer, NOS",UK,Northern Europe,Europe,More developed regions,Belfast City Hospital,,consecutive primary cancers,"SU, CX (platinum-based)",56.0,33-75,50,,survival,not related to,"No significant association was found between p53 status and overall survival or disease-free survival following chemotherapy. Likewise, there was no correlation between p53 mutation and response to chemotherapy as defined by normalization of CA125 levels. Tumours with p53 missense mutations recurred within a significantly shorter time than those with normal p53 (p=0.04). In addition, there was a tendency for tumours with missense mutations to have a shorter disease-free survival than those with non-missense mutations, although this did not reach statistical significance (p=0.07).",1512,,P53 mutation does not affect prognosis in ovarian epithelial malignancies,Fallows S;Price J;Atkinson RJ;Johnston PG;Hickey I;Russell SE;,2001,J Pathol,194,68,75,11329143,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
28,OVARY,OVARY,"Cancer, NOS",NA,NA,NA,NA,University of Southern California School of Medicine; Humboldt-University of Berlin,1972-1995,consecutive primary cancers,"SU, CX",31.0,1-144,178,99,survival/response,associated with bad,"p53 mutations were found in 56% (99 of 178) of the tumors, and 62% of these were located in evolutionary highly conserved domains of the gene. Time to progression and overall survival were significantly shortened in patients with p53 mutations compared with wild-type p53 (P = 0.029 and P = 0.014) and patients with mutations in highly conserved domains as opposed to nonconserved domains or wild-type p53 (P = 0.010 and P = 0.007). Resistance to adjuvant cisplatin or carboplatin chemotherapy was significantly more frequent in patients with p53 overexpression (P = 0.001) or p53 missense mutations (P = 0.008) than patients with normal p53.",1572,1180,Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer,Reles A;Wen WH;Schmider A;Gee C;Runnebaum IB;Kilian U;Jones LA;el Naggar A;Minguillon C;Schonborn I;Reich O;Kreienberg R;Lichtenegger W;Press MF;,2001,Clin Cancer Res,,,,11595686,,frozen,DNA,SSCP/none,direct,true,true,true,true,true,true,true,true,true,true,false
29,OVARY,OVARY,"Cancer, NOS",USA,Northern America,Americas,More developed regions,University of Iowa Hospitals and Clinics,1990-1996,consecutive primary cancers,"SU, CX",40.8,0-106.8,171,98,survival,associated with bad,"The nonresponsive p53 (wild-type [wt] p53 sequence, DO7 negative) and null sequence tumors grouped together as functionally null convey the worst prognosis relative to missense mutations in a univariate model (P = 0.006). Functionally null p53 (P = 0.002), stage (P = 0.008), and optimal cytoreduction (P = 0.008) were independent prognostic factors by multivariate analysis.",1648,707,The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma,Shahin MS;Hughes JH;Sood AK;Buller RE;,2000,Cancer,89,2006,2017,11064359,,frozen,DNA,SSCP,direct,true,true,true,true,true,true,true,true,true,true,false
60,OVARY,OVARY,"Cancer, NOS",The Netherlands,Western Europe,Europe,More developed regions,Hospitals from Southern Netherlands,1988-1993,primary cancer,"SU, CX",78.0,2-120,80,31,survival/response,not related to,"TP53 mutation, p21 and BCL-2 expression were not associated with increased rates of progression and death. Expression of TP53 was associated with a shorter overall survival only (relative hazard rate [RHR] 2.01, P = 0.03). When combining TP53 mutation and expression data, this resulted in an increased association with overall survival (P = 0.008). No relations were observed between tested factors and response to platinum-based chemotherapy.",1657,,"Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2",Schuyer M;van der Burg ME;Henzen-Logmans SC;Fieret JH;Klijn JG;Look MP;Foekens JA;Stoter G;Berns EM;,2001,Br J Cancer,85,1359,1367,11720475,,frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
86,OVARY,OVARY,"Carcinoma, NOS",USA,Northern America,Americas,More developed regions,"Gynecological Oncology Group (GOG 114, 132, 136)",,,"SU, CX (platinium-based or paclitaxel)",,,109,84,survival,associated with good,"A mutation in exons 2 to 11 of p53 was associated with a short-term improvement in overall survival and progression-free survival. Adjusted Cox modeling demonstrated a 70% reduction in risk of death (P =.014) and a 60% reduction in risk of disease progression (P =.014) for women with such mutations. However, these striking risk reductions increased over time (P <.02) and eventually disappeared with longer follow-up.",1813,,Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study,Havrilesky L;Darcy M;Hamdan H;Priore RL;Leon J;Bell J;Berchuck A;,2003,J Clin Oncol,21,3814,3825,14551300,,frozen,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
89,OVARY,OVARY,"Cancer, NOS",USA,Northern America,Americas,More developed regions,Holden Comprehensive Cancer Center of The University of Iowa,1990-1998,"primary, invasive epithelial",,,,267,125,survival,associated with bad,The presence of any null-mutation significantly compromised survival relative to the presence of any missense mutation (median survival 4.0 versus 1.9 years; p<0.01). P53-null mutation is an independent adverse prognostic factor for advanced stage ovarian cancer and is independent of the mutation mechanism.,1816,707,The impact of p53 protein core domain structural alteration on ovarian cancer survival,Rose SL;Robertson AD;Goodheart MJ;Smith BJ;DeYoung BR;Buller RE;,2003,Clin Cancer Res,9,4139,4144,14519637,"See also ref 976,1294,1518, 153 and, 1648. Only missense mutations reported.",fixed/frozen,DNA/RNA,none,direct,false,false,true,true,true,true,true,true,true,false,false
91,OVARY,OVARY,"Endometrioid adenocarcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Showa University Hospital,1987-1999,,"SU, CX (Platinium)",,,27,17,survival,associated with bad,"p53 mutation, which was found in 63% of EC tumors, is an independent prognostic factor for EC patients. However, no p53 mutation was found in OCCA tumors.",1818,1818,p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer,Okuda T;Otsuka J;Sekizawa A;Saito H;Makino R;Kushima M;Farina A;Kuwano Y;Okai T;,2003,Gynecol Oncol,88,318,325,12648581,See ref 1974,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
103,OVARY,OVARY,"Carcinoma, NOS",Norway,Northern Europe,Europe,More developed regions,"Norwegian Radium Hospital, Oslo",1982-1989,"Early stage cancers (FIGO IA, IB, IC)","SU, CX/RX",168.0,120-204,178,71,survival,not related to,"TP53 mutations were slightly less common in the Federation of Gynecologists and Obstetricians stage IA than in IB/IC (P=0.05). No significant correlations with histological type, grade of differentiation, DNA ploidy status or age at diagnosis were found. TP53 protein accumulation analysed by immunohistochemistry was found in 32.6% of all tumours, and was a poor predictor of TP53 mutations with 56.4% sensitivity, 77.1% specificity, 50% positive predictive value and 81.3% negative predictive value. Neither TP53 mutations nor TP53 protein accumulation influenced the prognosis significantly in this group of patients.",1918,,"TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival",Wang Y;Helland A;Holm R;Skomedal H;Abeler VM;Danielsen HE;Trope CG;Borresen-Dale AL;Kristensen GB;,2004,Br J Cancer,90,678,685,14760384,Only mutations in exons 5-8 were sequenced,fixed,DNA,TTGE,direct,true,true,true,true,true,true,true,true,true,true,false
113,OVARY,OVARY,"Carcinoma, NOS",USA,Northern America,Americas,More developed regions,"Memorial Sloan-Kettering Cancer Center, NY",1980-2000,"Early stage (FIGO I, II) primary cancers",,,0-240,68,22,survival,associated with bad,The 5-year PFS and DFS were significantly worse for carcinomas with a TP53 mutation (22.6% vs. 41.2% progressed [P =0.04]; 21.7% vs. 24.7% died [P = 0.04]).,1942,1941,Clinicopathologic analysis of early-stage sporadic ovarian carcinoma,Leitao MM;Boyd J;Hummer A;Olvera N;Arroyo CD;Venkatraman E;Baergen RN;Dizon DS;Barakat RR;Soslow RA;,2004,Am J Surg Pathol,28,147,159,15043303,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
115,OVARY,OVARY,"Carcinoma, NOS",Norway,Northern Europe,Europe,More developed regions,"Norwegian Radium Hospital, Oslo",1992-2003,primary cancers,"SU, CX (platinum-based)",23.0,2-116,109,80,survival,associated with bad,"Tumors homozygous or hemizygous for the Pro allele had significantly higher frequency of TP53 sequence variants, particularly of the nonmissense type (P=0.002), and patients with these types of alterations had significantly shorter survival (P=0.04). TP53 protein accumulation, determined by immunohistochemistry (IHC), was found in 67.9% (74 out of 109) of the tumors, was significantly more common among serous than nonserous ovarian carcinomas (P=0.008), and had a significant effect on progression-free survival (P=0.03). Follow-up study (Annals of Oncology, 2007): Analysis of progression-free and disease-specific survival in three mutation groups (very aggressive: missense mutations affecting amino acids directly involved in DNA or zinc binding in addition to other mutations with a Pro-Pro genotype, aggressive: missense mutations outside any conserved or structural domain with other genotypes than Pro-Pro, WT + neutral: wildtype, null mutations and the remaining missense mutations) revealed an independent poorer prognostic factor for progression-free survival (P = 0.022, hazard ratio = 5.26) and a trend regarding disease-specific survival (P = 0.054, hazard ratio = 3.72), International Federation of Gynaecology and Obstetrics stage, residual tumour after surgery, age, histology and grade being taken into consideration.",1949,1949,"Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma",Wang Y;Kringen P;Kristensen GB;Holm R;Baekelandt MM;Olivier M;Skomedal H;Hainaut P;Trope CG;Abeler VM;Nesland JM;Borresen-Dale AL;Helland A;,2004,Hum Mutat,24,21,34,15221786,See ref 2099,fixed/frozen,DNA,TTGE,direct,true,true,true,true,true,true,true,true,true,true,false
129,OVARY,OVARY,"Cancer, NOS",Denmark,Northern Europe,Europe,More developed regions,"Gynecologic departments in Denmark (Copenhagen, Frederiksberg, Roskilde, Western Zealand, Funen, Southern & Northern Jutland)",1994-1999,"Women between 35-79 years, preoperative, stage III and IV",,,0-90,74,15,survival,associated with bad,"Significantly shorter survival was found for stage III/IV patients with a p53 missense mutation compared to stage III/IV OC patients with wild type p53 (P = 0.0018). Multivariate Cox regression analysis restricted to 107 OC patients with a p53 missense mutation or p53 wild type in the tumor tissue and with information on radicality of primary surgery showed that missense p53 mutation (HR = 2.5, 95% CI: 1.21-4.98), radicality after primary surgery (HR = 1.7, 95% CI: 1.04-2.88), tetranectin (mg/l: HR = 0.78, 95% CI: 0.67-0.91) and stage (I vs. III: HR = 0.30, 95% CI: 0.10-0.92, II vs. III: HR = 0.24, 95% CI: 0.05-1.05, IV vs. III: HR = 2.70, 95% CI: 1.22-5.98) were independent prognostic factors. CONCLUSION: Missense mutations in the conserved regions of p53 may be of prognostic value in Danish OC patients.",2089,,P53 mutations in tissue from Danish ovarian cancer patients: from the Danish 'MALOVA' ovarian cancer study,Hogdall EV;Kjaer SK;Blaakaer J;Christensen L;Glud E;Vuust J;Hogdall CK;,2006,Gynecol Oncol,100,76,82,16183105,,frozen/fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
160,OVARY,OVARY,"Adenocarcinoma, NOS",Austria,Western Europe,Europe,More developed regions,"Innsbruck Medical University, Medical University of Vienna",,consecutive primary cancers,"SU, CX (various combination of platinium-based +- paclitaxel)",,26-212,122,80,recurrence/survival,associated with bad,"p53 mutational status was an important determinant of responsiveness to platinum-based chemotherapy in all patients with a residual tumor of <2 cm in diameter after initial surgery (wild-type versus mutant, P = 0.029). In addition, p53 mutational status was a strong prognosticator for recurrence-free and overall survival (P < 0.0001 and P = 0.003, respectively) in univariate analyses. Eight p53 mutations, present in 19 cases, were found that efficiently inhibit TAp73 (i.e., 175H, 220C, 245S, 245D, 248W, 248Q, 266E, and 273H). Patients with p53 mutations that efficiently inhibit TAp73 function had a significantly shorter overall survival than patients with p53 mutations of unknown effect on TAp73 (P = 0.044).",2180,,Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo,Concin N;Hofstetter G;Berger A;Gehmacher A;Reimer D;Watrowski R;Tong D;Schuster E;Hefler L;Heim K;Mueller-Holzner E;Marth C;Moll UM;Zeimet AG;Zeillinger R;,2005,Clin Cancer Res,11,8372,8383,16322298,,frozen,RNA,FASAY,cloned,true,true,true,true,true,true,true,true,true,true,false
33,PANCREAS,PANCREAS,"Cancer, NOS",Austria,Western Europe,Europe,More developed regions,University of Innsbruck,1977-1987,consecutive primary cancers,,14.8,1-69,71,29,survival,associated with bad,p53 mutations correlated with distant metastasis (p < 0.05) and survival (p < 0.05).,667,,"p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas",Weyrer K;Feichtinger H;Haun M;Weiss G;Ofner D;Weger AR;Umlauft F;Grunewald K;,1996,Lab Invest,74,279,289,0008569192,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
92,PANCREAS,PANCREAS,"Carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Shimane Medical University (Izumo),1982-2001,consecutive invasive ductal carcinomas,"SU, CX",,0-72,72,45,survival/response,associated with good,"Univariate analysis showed that in the p53 mutation group, the patients who received adjuvant chemotherapy had a better survival ratio than that of patients who did not do. Multivariate analysis indicated that in the group with p53 mutations, the significant factors for survival were adjuvant chemotherapy, histologic grade, and clinical stage. However, in the group with a wild-type p53 gene, only histologic grade was a significant factor. In addition, 34.7% (25/72) of the cases harbor p53 polymorphism mutation only at codon-72 of exon-4, which did not show any significant effect on the pathology, prognosis, and efficacy of adjuvant chemotherapy of the pancreatic cancers.",1819,,"p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer",Dong M;Nio Y;Yamasawa K;Toga T;Yue L;Harada T;,2003,J Surg Oncol,82,111,120,12561067,,fixed,DNA,none,direct,false,false,true,true,true,true,true,true,false,false,false
222,PANCREAS,PANCREAS,"Adenocarcinoma, NOS",USA,Northern America,Americas,More developed regions,The Johns Hopkins Medical Institutions,1989-2007,pancreaticoduodenectomy patients who survived at least 30 days,SU; RX; CX(5-FU),,1-48,89,75,survival,not related to,"TP53 gene mutation status did not correlate with survival (log-rank P = 0.21), even when adjusted for lymph node status, tumor grade, margin status, tumor size, and age [Fig. 3; hazard ratio, 1.41 (95% CI, 0.69-2.85); P = 0.34].",2563,2553,SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer,Blackford A;Serrano OK;Wolfgang CL;Parmigiani G;Jones S;Zhang X;Parsons DW;Lin JC;Leary RJ;Eshleman JR;Goggins M;Jaffee EM;Iacobuzio-Donahue CA;Maitra A;Cameron JL;Olino K;Schulick R;Winter J;Herman JM;Laheru D;Klein AP;Vogelstein B;Kinzler KW;Velculescu,2009,Clin Cancer Res,15,4674,4679,19584151,,,DNA,xenograft/cultured sple,direct,true,true,true,true,true,true,true,true,true,true,false
64,PROSTATE GLAND,PROSTATE,"Cancer, NOS",USA,Northern America,Americas,More developed regions,,,consecutive primary cancers,SU,,,58,8,survival,not related to,"p53 mutational status, but not overexpression, was associated with higher Gleason scores (p=0.0145). Neither p53 overexpression nor mutation was associated with clinical stage, biochemical disease-free probability, or predictive of response to radiotherapy. p53 protein accumulation was inversely associated with improved overall survival (p=0.0108). Our studies demonstrate that p53 protein accumulation is a frequent alteration in prostate cancer. The disparity between p53 protein overexpression and p53 exon 5-9 mutations suggests the possibility of mutations outside this region or stabilization of wild-type p53 by alternative mechanisms. In our patient population, p53 protein overexpression or mutational status was not predictive of outcome in patients treated with radiation therapy.",1660,,Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy,Incognito LS;Cazares LH;Schellhammer PF;Kuban DA;Van Dyk EO;Moriarty RP;Wright GL;Somers KD;,2000,Int J Oncol,17,761,769,10995889,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
191,PROSTATE GLAND,PROSTATE,"Cancer, NOS",USA,Northern America,Americas,More developed regions,"Universityof California, Davis and Kaiser Permanente North Medical Center, Sacramento, California",1989-1998,Radical prostectomy samples,,7.4,"2,6-12,9",98,44,survival,associated with bad,"When the p53 status of these patients was correlated with their clinical outcome, patients who had sequence-confirmed p53 mutations had a 2.6-fold greater failure rate (P = 0.026) and a 2.5-fold greater risk of dying from prostate cancer (P = 0.05). Notably, mutations in exon 6 predicted a six-fold increase in treatment failure (P = 0.043) and a 5.3-fold increase in the chance of dying from prostate cancer (P = 0.009). Abnormal yeast-assay findings gave similar predictive results to those obtained for DNA sequencing, while immunopositivity did not correspond to patient outcome.",1988,,A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value,Shi XB;Gandour-Edwards R;Beckett LA;Deitch AD;Vere White RW;,2004,BJU Int,94,996,1002,15541116,,,DNA,FASAY/IHC+SSCP,cloned,false,false,false,true,true,true,true,false,false,false,false
14,RECTUM,RECTUM,"Cancer, NOS",Finland,Northern Europe,Europe,More developed regions,National cancer registry,,female; case-control for RX (cervical cancer 10 years before RC),,32.0,0-306,98,38,survival,not related to,Mutation or overexpression of p53 were not associated with survival.,1643,1450,K-ras and p53 mutations and overexpressions as prognostic factors in female rectal carcinoma,Hirvikoski P;Auvinen A;Servomaa K;Kiuru A;Rytomaa T;Makkonen K;Kosma VM;,1999,Anticancer Res,19,685,691,10216477,,fixed,DNA,SSCP,direct,false,false,true,true,true,true,true,false,false,false,false
68,RECTUM,RECTUM,"Adenocarcinoma, NOS",Austria,Western Europe,Europe,More developed regions,Multicenter in Austria,,retrospective study; resectable cancer with preoperative short-term radiotherapy,"SU, pre-op RX (25 Gy)",,0-65,64,29,survival/response,associated with bad,"Mutations of the p53 gene were present in 45% of tumors. Patients with a normal p53 gene had a significant survival advantage. Comparing pre- and postradiotherapy T category, a reduction was seen in patients with normal p53 genotype only….downstaging after short-term radiation may occur but is seen in tumors with normal p53 gene only. Moreover, p53 genotype but not p53 immunohistochemistry is predictive for response to preoperative short-term radiotherapy and patient survival.",1675,,TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer,Kandioler D;Zwrtek R;Ludwig C;Janschek E;Ploner M;Hofbauer F;Kuhrer I;Kappel S;Wrba F;Horvath M;Karner J;Renner K;Bergmann M;Karner-Hanusch J;Potter R;Jakesz R;Teleky B;Herbst F;,2002,Ann Surg,235,493,498,11923604,,fixed,DNA,none,direct,true,true,true,true,true,true,true,true,true,false,false
77,RECTUM,RECTUM,"Adenocarcinoma, NOS",France,Western Europe,Europe,More developed regions,"Centre Hospitalier Lyon-Sud, Lyon",1989-1991,retrospective study,"SU, pre-op RX",48.0,1.5-81,86,44,survival/response,associated with bad,"The prevalence of p53 mutations was significantly higher in patients who did not respond to radiotherapy (63%) than in those who did respond (34%) (p < 0.01). Presence of a p53 mutation was associated with significantly shorter 5-year survival compared to patients without mutations (p < 0.02). In a multivariate analysis, p53 mutation status remained a prognostic factor independent of tumor posttreatment staging (p < 0.05). p53 status is an independent prognostic factor of response to radiotherapy and survival in rectal carcinoma.",1729,,Prognostic value of P53 mutations in rectal carcinoma,Rebischung C;Gerard JP;Gayet J;Thomas G;Hamelin R;Laurent-Puig P;,2002,Int J Cancer,100,131,135,12115559,,,DNA,DGGE,direct,true,true,true,true,true,true,true,true,true,true,false
130,RECTUM,RECTUM,"Carcinoma, NOS",France,Western Europe,Europe,More developed regions,"Val d'Aurelle Paul-Lamarque Cancer Institute, Montpellier",1996-2001,"life expectancy greater than 3 months, Who performance status of 0, 1 or 2","SU, pre-op RX",,,70,35,response,not related to,"Whatever the method of evaluation of treatment response, no correlation between p53 alterations and response to radiotherapy was observed. Our results do not support the use of p53 alterations alone as a predictive marker for response to radiotherapy in rectal carcinoma.",2090,,p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis,Lopez-Crapez E;Bibeau F;Thezenas S;Ychou M;Simony-Lafontaine J;Thirion A;Azria D;Grenier J;Senesse P;,2005,Br J Cancer,92,2114,2121,15956964,,frozen/fixed,RNA,none,direct,true,true,true,true,true,true,true,true,true,true,false
42,RENAL PELVIS,RENAL PELVIS,"Transitional cell carcinoma, NOS",Australia,Australia/New Zealand,Western Pacific,More developed regions,New South Wales Central Cancer Registry,1989-1990,consecutive primary cancers,,,0-72,89,29,survival,associated with bad,Patients with carcinomas carrying a p53 mutation showed poorer survival than those without mutation.,1018,,Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes,Bringuier PP;McCredie M;Sauter G;Bilous M;Stewart J;Mihatsch MJ;Kleihues P;Ohgaki H;,1998,Int J Cancer,79,531,536,0009761125,,fixed,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
72,ACCESSORY SINUSES,SINUSES,"Squamous cell carcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,Asahikawa Medical College,1980-2000,consecutive primary cancers,"SU, pre-op RX/CX",61.0,2-189,70,20,survival,associated with bad,"Kaplan-Meier analysis as well as univariate analysis using the Cox proportional hazards model showed that low histologic effectiveness of radiochemotherapy (P = 0.0281, P = 0.0284, respectively), p53 mutations (P = 0.0095, P = 0.0187, respectively), negativity of bax (P = 0.0069, P = 0.0191, respectively), and low AI (P = 0.0134, P = 0.0407, respectively) were significantly related to worse disease-free survival. Multivariate analysis showed AI as an independent factor predicting for disease-free survival (P = 0.0455).",1693,,"Prognostic value of p53 mutations, bax, and spontaneous apoptosis in maxillary sinus squamous cell carcinoma",Bandoh N;Hayashi T;Kishibe K;Takahara M;Imada M;Nonaka S;Harabuchi Y;,2002,Cancer,94,1968,1980,11932899,,fixed,DNA,none,direct,false,false,false,true,true,true,true,false,false,false,false
117,ACCESSORY SINUSES,SINUSES,"Adenocarcinoma, intestinal type (C16._)  ",Italy,Southern Europe,Europe,More developed regions,Instituto Nazionale Tumori Milano,1996-2003,consecutive primary cancers,"CX, SU, RT",,,30,18,response,associated with bad,"In patients with wild-type (wt) TP53 or functional p53 protein, the pathologic complete remission (pCRs) were 83% and 80%, respectively; in patients with mutated TP53 or impaired p53 protein, pCRs were 11% and 0%, respectively (P < or = .0001).",1992,,"Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma",Licitra L;Suardi S;Bossi P;Locati LD;Mariani L;Quattrone P;Lo VS;Oggionni M;Olmi P;Cantu G;Pierotti MA;Pilotti S;,2004,J Clin Oncol,22,4901,4906,15611505,,fixed,DNA,DGGE,direct,false,false,false,true,true,true,true,false,false,false,false
81,"CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES",SOFT TISSUES,"Sarcoma, NOS",Germany,Western Europe,Europe,More developed regions,"Institute of Pathology and Surgical clinic, University of Halle",,consecutive primary cancers,"SU, CX/RX",,1-168,145,15,survival/response,associated with bad,"Patients possessing non-fs mutations had a significantly poorer prognosis than patients without p53 mutations (P = 0.014), according to Cox's multivariate analysis.",657,552,Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients,Taubert H;Meye A;Wurl P;,1996,Cancer Res,56,4134,4136,0008797580,See ref 552,fixed,DNA,SSCP,direct,false,false,true,true,true,true,true,true,false,false,false
151,"CONNECTIVE, SUBCUTANEOUS AND OTHER SOFT TISSUES",SOFT TISSUES,Mixed liposarcoma,Japan,Eastern Asia,Asia,More developed regions,"Kyushu University Hospital, Fukuoka",1971-2003,,SU,76.6,2-393,64,8,survival,associated with bad,"Patients with p53 mutation (p=0,0328) or with p53 missense mutation (p=0,0111) had a worse survival than those with no p53 mutation. In MLS/RCLS, reduction of p14 protein expression and p53 mutation were related to poor prognosis. Accordingly, the p14(ARF)/p53 pathway may contribute to the presence of an RC component and malignant progression in this tumour.",2152,,Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis,Oda Y;Yamamoto H;Takahira T;Kobayashi C;Kawaguchi K;Tateishi N;Nozuka Y;Tamiya S;Tanaka K;Matsuda S;Yokoyama R;Iwamoto Y;Tsuneyoshi M;,2005,J Pathol,207,410,421,16177957,,fresh/frozen,DNA,SSCP,direct,false,false,false,true,true,true,true,true,false,false,false
88,STOMACH,STOMACH,"Cancer, NOS",Germany,Western Europe,Europe,More developed regions,Regensburg,1996-2000,advanced stages,,13.0,3-50,25,8,survival/response,associated with good,"Four parameters were significantly associated with response to chemotherapy and prolonged overall survival: positive p53 immunostaining, positive p53 mutation status before chemotherapy, strong histological regression induced by preoperative HDCT, and surgical treatment.",1815,,Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer,Bataille F;Rummele P;Dietmaier W;Gaag D;Klebl F;Reichle A;Wild P;Hofstadter F;Hartmann A;,2003,Mol Pathol,56,286,292,14514923,,fixed,DNA,none,direct,false,false,false,true,true,true,true,true,false,false,false
102,STOMACH,STOMACH,"Carcinoma, NOS",Germany,Western Europe,Europe,More developed regions,"Institute of Pathology, Klinikum rechts des Isar, Munich",,advanced stages,CX (CISP-based),46.0,20-103,53,19,survival/response,not related to,p53 mutations were identified in 19 of the 53 (36%) analyzed tumors. No significant association with response or survival was found for p53 mutation or for p53 protein expression.,1883,,Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma,Ott K;Vogelsang H;Mueller J;Becker K;Muller M;Fink U;Siewert JR;Hofler H;Keller G;,2003,Clin Cancer Res,9,2307,2315,12796400,,fixed,DNA,DHPLC,direct,true,true,true,true,true,true,true,true,true,true,false
116,STOMACH,STOMACH,"Adenocarcinoma, NOS",Italy,Southern Europe,Europe,More developed regions,University of Palermo,1992-1996,consecutive primary cancers,"SU, CX",,0-60,62,17,survival,associated with bad,"Specific mutations in functional domain (L3 and LSH), together with advanced TNM stage, node involvement, depth of invasion, diffuse histotype, proved to be significantly related to quicker relapse and to shorter overall survival.",1962,,TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome,Migliavacca M;Ottini L;Bazan V;Agnese V;Corsale S;Macaluso M;Lupi R;Dardanoni G;Valerio MR;Pantuso G;Di Fede G;Tomasino RM;Gebbia N;Mariani-Costantini R;Russo A;,2004,J Cell Physiol,200,476,485,15254976,,fresh,DNA,SSCP,direct,false,false,false,true,true,true,true,false,false,false,false
131,STOMACH,STOMACH,"Adenocarcinoma, NOS",Japan,Eastern Asia,Asia,More developed regions,"Department of Surgery II, Kyushu University Hospital, Fukuoka",1996-2000,,,,0-60,213,19,survival,not related to,"Kaplan–Meier overall survival curve demonstrates that patients with mutant p53 had a relatively higher survival rate than those patients with wild type p53, however, it was not significant.",2093,,Genetic mutual relationship between PTEN and p53 in gastric cancer,Oki E;Tokunaga E;Nakamura T;Ueda N;Futatsugi M;Mashino K;Yamamoto M;Watanabe M;Ikebe M;Kakeji Y;Baba H;Maehara Y;,2005,Cancer Lett,227,33,38,16051030,,frozen,DNA,none,direct,false,false,true,true,true,true,true,false,false,false,false
185,STOMACH,STOMACH,"Adenocarcinoma, NOS",Germany,Western Europe,Europe,More developed regions,"Klinikum Rechts der Isar, Technical University of Munich",2000-2004,"uT3 or uT4 tumors, no metastasis","SU, pre-op CX",11.0,2-57,38,23,survival/response,not related to,"The 2-year survival rate of patients with p53 mutated tumors was lower (51,5%) thant that of patients with p53 wild-type tumors (66,9%). This difference marginally failed to achieve statistical significance (P=0,0832).",2332,,Lack of prognostic impact of p53 gene mutation and p53 phosphorylation at serine 15 in multimodally treated adenocarcinomas of the gastroesophageal junction,Puhringer-Oppermann F;Stahl M;Keller G;Sarbia M;,2006,J Cancer Res Clin Oncol,132,433,438,16538517,,fixed,DNA,DHPLC,direct,false,false,false,true,true,true,true,false,false,false,false
